

# UTILITY CONTINUATION-IN-PART PATENT APPLICATION TRANSMITTAL

(Only for Continuation-in-Part applications under 37 CFR 1.53(b))

Attorney Docket No.: 4228-1-1-1

Inventors: Gerald Soff of 8651 North Kedvale, Skokie, Illinois 60076  
Stephen T. Gately of 1325 Sterling Avenue, Palatine, Illinois 60067  
Przemyslaw Twardowski of 4061 N. Sheridan Road, Unit 1, Chicago, Illinois 60613

Express Mail Label No.: EL417662786

Title: METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

This is a continuation-in-part of pending application Serial No. 08/991,761, filed December 15, 1997, which was a continuation-in-part of pending application Serial No. 08/710,305, filed September 17, 1996. Benefit of PCT application PCT/US97/16539 filed September 17, 1997 is also claimed. The entire disclosure of the prior applications is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference.

Enclosed for filing with the above-identified utility patent application are the following:

1. Specification (Total Pages of Text, including Abstract and Claims: **58**)
2. Drawing(s) (35 USC 113) (Total Sheets: **15** Informal)
3. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. Computer Readable Copy
  - b. Paper Copy (identical to computer copy)
  - c. Attorney for applicants hereby asserts pursuant to 37 CFR § 1.821(f) that the content of the paper and computer readable copies of SEQ ID No:1 through SEQ ID No:17 submitted herewith are identical
4. Return Postcard (MPEP 503) (should be specifically itemized)

## FEE CALCULATION:

	(COL. 1) NO. FILED			(COL. 2*) NO. EXTRA	SMALL ENTITY			LARGE ENTITY	
					RATE	FEE		RATE	FEE
BASIC FEE:						\$345.00	OR		\$690.00
TOTAL CLAIMS:	58	-	20	38	X \$9 =	\$342.00	OR	X \$18 =	
INDEP. CLAIMS:	13	-	3	10	X \$39 =	\$390.00	OR	X \$78 =	
____ MULTIPLE DEPENDENT CLAIMS					+ \$130 =	\$	OR	+ \$260 =	
*IF THE DIFFERENCE IN COL. 2 IS LESS THAN ZERO, ENTER "O" IN COL. 2.					TOTAL:	\$1,077.00			

## OTHER INFORMATION:

1. **NO FEE IS ENCLOSED**
2. The Commissioner is hereby authorized to charge all required fees for extensions of time only under §1.17 to Deposit Account No. 19-1970.
3. Correspondence Address:

Wannell M. Crook  
SHERIDAN ROSS P.C.  
1560 Broadway, Suite 1200  
Denver, Colorado 80202-5141  
Telephone: (303) 863-9700  
Facsimile: (303) 863-0223

Respectfully Submitted,  
SHERIDAN ROSS P.C.

Wannell M. Crook  
Wannell M. Crook  
Registration No. 31,071

Date: Feb. 8, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
APPLICATION FOR UNITED STATES LETTERS PATENT

INVENTORS:

Gerald Soff  
Stephen Gately  
Przemyslaw Twardowski

TITLE:

METHODS AND COMPOSITIONS  
FOR GENERATING ANGIOSTATIN

ATTORNEYS:

Wannell M. Crook  
SHERIDAN ROSS P.C.  
1560 Broadway, Suite 1200  
Denver, Colorado 80202-5141  
(303) 863-9700

## METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN

This application is a continuation-in-part of pending application Serial No. 08/991,761, filed December 15, 1997, which was a continuation-in-part of pending application Serial No. 08/710,305, filed September 17, 1996. Benefit of PCT application PCT/US97/16539 filed September 17, 1997 is also claimed.

This invention was made, in part, with Government support received from the National Cancer Institute, grant number CA71875. The Government may have rights in the invention.

### FIELD OF THE INVENTION

This invention relates to angiostatin, an inhibitor of angiogenesis.

### BACKGROUND OF THE INVENTION

Angiostatin, a proteolytic fragment of plasminogen believed to consist of kringle 1 through 3 and all or part of kringle 4, is a potent inhibitor of angiogenesis and the growth of tumor cell metastases. O'Reilly et al., *Cell*, **79**, 315-328 (1994); PCT application WO 95/29242. Angiostatin is found *in vivo* in tumor-bearing mice. O'Reilly et al., *Cell*, **79**, 315-328 (1994); O'Reilly et al., *Nature Med.* **2**, 689-692 (1996). The enzymatic mechanism by which angiostatin is generated *in vivo* remains unknown.

Angiostatin activity can be generated *in vitro* by limited elastase proteolysis of plasminogen. Sottrup-Jensen et al., in *Progress in Chemical Fibrinolysis and Thrombolysis*, **3**, 191-209 (Davidson et al. eds. 1978). A recent abstract proposes that angiostatin is generated by macrophages infiltrating primary tumors and releasing elastase activity, which then cleaves plasminogen to form a protein having angiostatin activity. Dong et al., *Proc. Am. Assoc. Cancer Res.*, **37** 58 (1996). However, while limited elastase cleavage of plasminogen will yield a fragment or fragments having angiostatin activity, elastase will further digest the fragment(s) to inactive peptides, and therefore, is probably not the enzyme that generates angiostatin *in vivo*.

As noted above, angiostatin may be generated *in vitro* by limited elastase proteolysis of plasminogen. This method has several disadvantages. First, while elastase cleaves plasminogen to generate a fragment containing kringle 1-3, it is not known if this cleavage is at the normal sites where cleavage occurs to produce angiostatin *in vivo*. Therefore, the elastase-derived angiostatin may have altered *in vivo* processing with altered activity in humans. It may also be immunogenic if the sites of peptide cleavage are different from normal angiostatin.

A second means of producing angiostatin is by expressing the desired kringle domains of the plasminogen cDNA or gene in an expression vector in prokaryotic or eukaryotic cells. See PCT application WO 95/29242. This approach is also limited since the appropriate domains to express are not known. The product may also be immunogenic and may not be processed in humans as would be the product generated by cleavage of plasminogen by the normal *in vivo* enzymes.

Finally, angiostatin can be isolated from the body fluids of animals in which it is produced. See PCT application WO 95/29242. However, angiostatin cannot be produced in sufficient quantities for disease treatment in this manner, and the angiostatin may be contaminated with infectious agents when isolated from such sources.

Clearly a need exists for a method of producing native angiostatin in large quantities. "Native angiostatin" is defined herein to be the angiostatin produced *in vivo* or angiostatin, no matter how produced, which is the same as the angiostatin produced *in vivo*.

#### SUMMARY OF THE INVENTION

The present invention provides such methods. These methods are based on the discovery that a conditioned culture medium (CCM) produced by culturing cancer cells, primary endothelial cells, smooth muscle cells or fibroblasts produces angiostatin when contacted with plasminogen or plasmin. The active factors in the CCM have been identified to be a plasminogen activator and a sulfhydryl donor. Thus, the angiostatin produced by the

use of a plasminogen activator and sulfhydryl donor is the same as angiostatin produced *in vivo*, i.e., it is native angiostatin.

In one method of the invention for producing angiostatin *in vitro*, plasmin is contacted with a sulfhydryl donor to produce the angiostatin. The plasmin may be generated by contacting plasminogen with a plasminogen activator. Most conveniently, all of the reactants (plasminogen, plasminogen activator and sulfhydryl donor) can be contacted simultaneously to produce the angiostatin.

The angiostatin produced by this method, along with any remaining reactants, or angiostatin purified or partially purified from the reactants, may be administered to an animal, including a human, in need thereof. Animals in need of angiostatin are animals suffering from an angiogenic disease.

The invention further provides a composition for generating angiostatin. The composition comprises a sulfhydryl donor and a plasminogen activator. Two embodiments of the composition are CCM produced by culturing cells capable of producing plasminogen activator and a lysate of such cells.

The invention also provides a method of treating an angiogenic disease comprising administering to an animal suffering from such a disease an amount of a sulfhydryl donor effective to cause the conversion of plasmin to angiostatin. The plasmin may be that produced by endogenous plasminogen activator(s) from endogenous plasminogen. Alternatively, the method may further comprise administering an effective amount of plasmin. In yet other embodiments, a plasminogen activator may be administered to the animal to produce the plasmin from endogenous plasminogen or from an effective amount of administered plasminogen.

The invention also provides a method of treating an angiogenic disease comprising administering to an animal suffering from such a disease an amount of a plasminogen activator effective to cause the conversion of plasminogen (endogenous plasminogen or administered plasminogen) to plasmin. Endogenous or administered sulfhydryl donors then cause the conversion of the plasmin to angiostatin.

The invention further provides a container holding a plasminogen activator, alone or in combination with sulfhydryl donor. The container has a label thereon instructing administration of the plasminogen activator or the combination of the plasminogen activator and sulfhydryl donor to an animal suffering from an angiogenic disease. The invention also provides a container holding a sulfhydryl donor with a label thereon instructing administration of the sulfhydryl donor in an amount effective to cause the conversion of plasmin to angiostatin.

The invention also provides a protein having the following characteristics: (a) it is a fragment of plasminogen; (b) its N-terminal amino acid is the same as the N-terminal amino acid of plasmin; (c) its C-terminal amino acid is in kringle 5; and (d) it inhibits angiogenesis. In one embodiment, the protein is native angiostatin. The invention further provides a DNA molecule coding for the protein, the DNA molecule operatively linked to expression control sequences, a host cell comprising the DNA molecule operatively linked to expression control sequences, and a method of producing the protein comprising culturing the host cell.

The protein may be used to treat angiogenic diseases by administering an effective amount of the protein to an animal suffering from such a disease. An animal suffering from such a disease may also be treated by administering to it a transgene coding for the protein. Preferably, the protein coded for by the transgene is native angiostatin.

Finally, the invention provides an antibody which binds selectively to the protein. Such an antibody may be used to purify the protein from materials containing it. Also, such an antibody which binds selectively to native angiostatin may be used in methods and kits to detect or quantitate native angiostatin.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A: Western blot showing conversion of plasminogen and plasmin to angiostatin by serum-free conditioned medium (SFCM) produced by PC-3 cells. Lane 1, molecular weight standard; lane 2, human plasminogen; lane 3, human plasminogen

incubated overnight at 37°C in non-conditioned RPMI; lane 4, human plasminogen incubated overnight at 37°C in SFCM from PC-3 cells; lane 5, human plasmin incubated in non-conditioned RPMI; lane 6, human plasmin incubated in SFCM produced by PC-3 cells.

Figure 1B: Western blot showing that the generation of angiostatin from plasminogen was time dependent. PC-3 SFCM was incubated with plasminogen and, at the time-points indicated, aliquots were removed and snap frozen prior to western blot analysis. Trace generation of angiostatin was first observed at 3 hours, and complete conversion was noted at 24 hours.

Figure 1C: Western blots showing that the generation of angiostatin by PC-3 SFCM was concentration dependent. SFCM was diluted with various amounts of fresh RPMI as indicated and incubated with plasminogen for 24 hours.

Figure 1D: Graph illustrating the relationship of angiostatin generation to the amount of SFCM. The relative angiostatin signal was quantitated by scanning densitometer with background subtraction. At 18 hours incubation, there was a linear relationship between the amount of angiostatin generated and the amount of PC-3 SFCM present in the reaction mixture.

Figure 2: Western blots after affinity purification of angiostatin generated by incubation of plasminogen with SCFM produced by PC-3 cells. Lane 1, molecular weight standards; lane 2, human plasminogen incubated overnight at 37°C in non-conditioned RPMI; lane 3, angiostatin produced by incubation of plasminogen with PC-3 SCFM and then affinity purified on lysine-sepharose and detected on western blot by staining with Coomassie blue; lane 4, angiostatin produced by incubation of plasminogen with PC-3 SCFM and then affinity purified on lysine-sepharose and detected on western blot using the monoclonal antibody K1-3 to kringles 1-3.

Figures 3A-B: Graphs showing that angiostatin produced by incubating plasminogen with PC-3 SCFM inhibits *in vitro* steps critical for angiogenesis. Figure 3A: Endothelial cell proliferation. The data are mean  $\pm$  standard deviation. Figure 3B: Basic fibroblast growth factor (bFGF)-induced migration. Background migration without the inducer and in the

presence of stimulatory bFGF are indicated. Toxicity was measured in parallel by trypan blue exclusion and was <10% at all concentrations.

Figures 4A-B: Photographs showing that angiostatin produced by incubating plasminogen with PC-3 SCFM inhibits human endothelial cell tube formation *in vitro*. Human umbilical vein endothelial cells (HUVEC) were plated on gels of Matrigel in 24-well dishes and then were treated with 15 µg/ml of angiostatin produced using PC-3 SFCM in non-conditioned RPMI. Figure 4A: Control HUVEC form branching, interconnecting networks. Figure 4B: By contrast angiostatin produced using PC-3 SFCM caused a significant disruption of the tube network.

Figures 5A-B: Photographs showing the inhibition of angiogenesis *in vivo* by angiostatin produced using PC-3 SCFM. Figure 5A: A hydron pellet (indicated by the arrow) containing bFGF induced a positive neovascular response 7 days after implantation. Figure 5B: By contrast, no vessels are observed approaching a hydron pellet containing bFGF and 10 µg/ml angiostatin produced using PC-3 SFCM (indicated by the arrow).

Figure 6: Western blot showing that the batch eluate from Reactive Red 120-Agarose generates angiostatin when combined with Reactive Red 120-Agarose flow-through, RPMI or RPMI amino acids. Lane 1 - SFCM + plasminogen; Lane 2 - Reactive Red 120-Agarose flow-through + plasminogen; Lane 3 - Reactive Red 120-Agarose batch eluate after dialysis to TBS + plasminogen; Lane 4 - dialyzed batch eluate + Reactive Red 120-Agarose flow-through + plasminogen; Lane 5 - dialyzed batch eluate + RPMI + plasminogen; Lane 6 - dialyzed batch eluate + RPMI vitamin mix + plasminogen; Lane 7 - dialyzed batch eluate + RPMI amino acid mix + plasminogen; Lane 8 - dialyzed batch eluate + RPMI vitamin mix and amino acid mix + plasminogen; Lane 9 - plasminogen + unconditioned RPMI.

Figure 7: Graph showing that urokinase-type plasminogen activator (u-PA) activity and plasminogen-angiostatin converting activity (PACA) co-elute on a gradient elution from Hi-Q anion exchange column. Optical density readings at 280 nm demonstrated several protein peaks. u-PA activity was determined by measuring the cleavage of a chromogenic



peptide substrate for plasmin (Val-Leu-Lys *p*-NA) at 405 nm. The peak fractions were assayed for PACA by western blot.

**Figure 8:** Western blot showing that addition of u-PA and plasminogen to boiled Reactive Red 120-Agarose flow-through or fresh RPMI medium generated angiostatin. Lane 1 - Reactive Red 120-Agarose flow-through + plasminogen; Lane 2 - Reactive Red 120-Agarose flow-through + plasminogen + u-PA; Lane 3 - Reactive Red 120-Agarose boiled flow-through + plasminogen; Lane 4 - Reactive Red 120-Agarose boiled flow-through + plasminogen + u-PA; Lane 5 - unconditioned RPMI + plasminogen; Lane 6 - unconditioned RPMI + plasminogen + u-PA.

**Figure 9:** Western blot showing that the Reactive Red 120-Agarose flow-through produces angiostatin in the presence of plasminogen activators. Lane 1 - Reactive Red 120-Agarose flow-through + plasminogen; Lane 2 - Reactive Red 120-Agarose flow-through + plasminogen + u-PA; Lane 3 - Reactive Red 120-Agarose flow-through + plasminogen + t-PA.

**Figure 10:** Western blot showing the production of angiostatin by u-PA and glutathione. Lane 1 - plasminogen + u-PA; Lane 2 - plasminogen + u-PA + 5  $\mu$ M glutathione; Lane 3 - plasminogen + u-PA + 50  $\mu$ M glutathione; Lane 4 - plasminogen + u-PA + 100  $\mu$ M glutathione; Lane 5 - plasminogen + u-PA + boiled 5  $\mu$ M glutathione; Lane 6 - plasminogen + u-PA + boiled 50  $\mu$ M glutathione; Lane 7 - plasminogen + u-PA + boiled 100  $\mu$ M glutathione.

**Figure 11:** Western blot showing that the combination of u-PA and D-penicillamine produces angiostatin. Lane 1 - plasminogen + 100  $\mu$ M D-penicillamine; Lane 2 - plasminogen + u-PA + 100  $\mu$ M D-penicillamine; Lane 3 - plasminogen + u-PA + 1.0 mM D-penicillamine.

**Figure 12:** Western blot showing the production of angiostatin by u-PA, t-PA and streptokinase. The abbreviations used in the figure have the following meanings:

PLG = human plasminogen;  
uPA = urokinase-type plasminogen activator;

tPA = tissue-type plasminogen activator;  
 SK = streptokinase;  
 + = with N-acetyl-L-cysteine; and  
 - = without N-acetyl-L-cysteine.

**Figure 13:** Western blot showing the production of plasmin from plasminogen and the production of angiostatin from the pre-formed, purified plasmin. Lane 1 - plasminogen + u-PA-Sepharose; Lane 2 - purified plasmin + 100  $\mu$ M N-acetyl-L-cysteine.

**Figure 14:** Graph of mean primary tumor size ( $\text{mm}^3$ ) for days 0-21 for control mice and mice treated with N-acetyl-L-cysteine (NAC) or NAC + urokinase-type plasminogen inhibitor (uPA).

**Figure 15:** Western blot showing the production of angiostatin by N-acetyl-L-cysteine (NAC) *in vivo*. Lane 1 - plasma (diluted 1:20) from control mouse #2; Lane 2 - plasma (diluted 1:20) from control mouse #3; Lane 3 - plasma (diluted 1:20) from first mouse receiving affinity-purified, cell-free angiostatin; Lane 4 - plasma (diluted 1:20) from second mouse receiving affinity-purified, cell-free angiostatin; Lane 5 - plasma (diluted 1:20) from NAC-treated mouse #1; Lane 6 - plasma (diluted 1:20) from NAC-treated mouse #2; Lane 7 - plasma (diluted 1:20) from NAC-treated mouse #3; and Lane 8 - affinity-purified, cell-free angiostatin.

**Figure 16:** A diagram of human plasminogen showing the amino acid sequence of the complete molecule after cleavage of the signal peptide (not shown) (taken from *Molecular Basis of Thrombosis and Hemostasis* (High and Roberts, eds. 1995)). Kringles 1-5 (K1-K5) are indicated. The cleavage sites between residues 77 and 78 and residues 561 and 562 needed for activation of plasminogen to plasmin are indicated by filled arrows. The unfilled arrows represent the positions of introns in the gene. The locations of the N-linked oligosaccharide at position 289 and the O-linked glycan at position 346 are also indicated. The \* indicate members of the catalytic triad of plasmin (His603, Asp646 and Ser741).

**Figure 17A.** A Western blot of plasma samples from a patient with a mesothelioma of the right hemi-thorax (Case #2 - see Table 4 below) treated with urokinase alone (Cycle

2) and subsequently with captopril and urokinase (Cycle 5). Lane 1: Cycle 2, Day 1, Pre-Treatment. Lane 2: Cycle 2, Day 3, Post-Treatment. Lane 3: Cycle 5, Day 1, Pre-Treatment. Lane 4: Cycle 5, Day 3, Post-Treatment. A "Cycle" for this patient refers to the three days of treatment plus the days off treatment until the therapy was begun again (see Table 4 below).

Figure 17B. Graph of cell numbers versus various amounts of the lysine-binding fractions of platelet-poor plasma samples taken from Case #2 in Cycle 2, Day 3 (solid bars) and Cycle 5, Day 3 (stippled bars) in a cell proliferation assay.

#### DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

The invention provides *in vitro* methods of generating native angiostatin. One such method comprises contacting plasminogen with a plasminogen activator and a sulfhydryl donor. All three of the reactants may be combined simultaneously. Alternatively, the plasminogen may be contacted with a plasminogen activator to produce plasmin, and the plasmin then contacted with a sulfhydryl donor to produce the angiostatin. The plasmin may be at least partially purified prior to contacting it with the sulfhydryl donor. Indeed, angiostatin can be produced directly from plasmin, however made, by contacting the plasmin with a sulfhydryl donor.

The plasminogen may be from any animal species. Preferably, however, plasminogen from the species of animal to be treated with the angiostatin is used to avoid immune reactions upon administration of the angiostatin. Thus, if a human is to be treated with the angiostatin, human plasminogen is preferably used.

Methods of making plasminogen are well known in the art. Plasminogen may also be purchased commercially. Preferably the plasminogen is prepared by recombinant DNA or other techniques that avoid the inclusion of infectious agents in the plasminogen preparation.

All types of plasminogen activators may be used, including urokinase-type plasminogen activators, tissue-type plasminogen activators and streptokinase. The plasminogen activator may be from any animal species. Methods of making plasminogen activators are well known in the art, and many plasminogen activators are available commercially. Preferably the plasminogen activator is prepared by recombinant DNA or other techniques that avoid the inclusion of infectious agents in the plasminogen activator preparation.

The plasminogen is contacted with the plasminogen activator in amounts and under conditions effective to cause the conversion of the plasminogen to plasmin. These amounts and conditions are known or can be determined empirically as is known in the art. In particular, from about 1 ng/ml to about 1 µg/ml of urokinase plasminogen activator for each microgram of plasminogen in a 1 ml reaction have been found to give complete conversion of plasminogen to plasmin after about 24 hours of incubation at 37°C.

Any sulfhydryl donor may be used. Sulfhydryl donors are well known and are available commercially. Suitable sulfhydryl donors include L-cysteine, D-cysteine, DL-cysteine, N-acetyl-L-cysteine, reduced glutathione, D-penicillamine and captopril. The sulfhydryl donor is believed to reduce or alter disulfide bond formation in the plasminogen, and/or the plasmin, and/or the angiostatin, and/or an intermediate product.

The sulfhydryl donor is contacted with the plasmin, alone or in the presence of the plasminogen and plasminogen activator, in amounts and under conditions effective to cause the conversion of the plasmin to angiostatin. These amounts and conditions can be determined empirically as is known in the art. In particular, from about 10 µM to about 1 mM of sulfhydryl donor for each microgram of plasmin in a 1 ml reaction have been found to give complete conversion of plasmin to angiostatin after about 24 hours of incubation at 37°C.

Plasmin may be generated from plasminogen by a plasminogen activator as described above. The plasmin may be purified from the reactants prior to contacting it with the sulfhydryl donor. Methods of purifying plasmin are known in the art (see, *e.g.*, Example 4).

Plasmin purchased commercially or prepared in other ways may also be used to produce angiostatin by contacting the plasmin with a sulfhydryl donor as described above.

The invention further provides a composition for generating angiostatin. The composition comprises a plasminogen activator and a sulfhydryl donor as described above. The plasminogen activator and sulfhydryl donor may be contained in any physiologically-acceptable solution (*e.g.*, saline, buffers, culture medium) or may be present in crystalline or lyophilized form. Compositions suitable for therapeutic use are described below.

The composition may be a conditioned culture medium (CCM) prepared by culturing cells capable of producing plasminogen activator. Malignant animal cells, human and non-human, which express a plasminogen activator can produce CCM capable of converting plasminogen and plasmin into angiostatin. Suitable malignant cells include human prostate carcinoma cell lines PC-3, DU-145, LN-CaP, human breast carcinoma cell lines MDA-MB-231 and MCF-7, human glioma cell lines U-373, U-118, A-172, and U-87, and mouse melanoma cell line B16F10. Many non-malignant animal cells are known to produce plasminogen activator. Suitable non-malignant cells include primary endothelial cells (*e.g.*, bovine aortic endothelial cells), smooth muscle cells (*e.g.*, bovine smooth muscle cells), and fibroblasts. In addition, bacterial cells are known which produce plasminogen activator (*e.g.*, streptokinase), and cells of any type can be transformed by recombinant DNA techniques to produce plasminogen activator. Suitable cells and cell lines are well known in the art and may be obtained commercially, from cell depositories, and by methods well known in the art.

Suitable culture conditions for these cells are also well known in the art. The culture medium used must contain a sulfhydryl donor, or a sulfhydryl donor may be added to the CCM after it is produced. Suitable culture media include those available commercially, such as RPMI, DMEM, etc. The CCM may be produced by simply culturing the cells under normal culture conditions for a sufficient time to produce CCM capable of converting plasminogen or plasmin to angiostatin. This time can be determined empirically. In particular, it has been found that culturing the mammalian cells for 24-72 hours after a monolayer has formed at 37°C is sufficient.

Alternatively, or in addition, the cells can be lysed after culturing for a time sufficient to allow synthesis of plasminogen activator. This time can be determined empirically, but culturing the cells until a monolayer has formed should be sufficient. The lysate can be used to convert plasminogen and plasmin to angiostatin.

The angiostatin produced by these methods may be purified from the reaction mixture. Methods of protein purification are well known in the art. In particular, angiostatin may be purified by affinity chromatography using lysine-Sepharose. Residual plasmin activity should be removed with, *e.g.*, soybean trypsin inhibitor-Sepharose, aprotinin-Sepharose, or other affinity chromatography procedures that remove serine proteases or the plasmin catalytic domain. The angiostatin may also be purified from the reaction mixture using an antibody that binds selectively to it (see below).

The angiostatin produced by these methods (native angiostatin) has been characterized. It reacts with a monoclonal antibody specific for kringles 1-3 of plasminogen and has been found to inhibit angiogenesis as assessed by a variety of tests *in vitro* and *in vivo*.

It has also been found to have the N-terminal sequence of plasmin. For angiostatin produced from human plasminogen, the N-terminal sequence has been found to be Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly [SEQ ID NO:1]. The sequences of the plasmin of other animals are known. Thus, native angiostatin of a particular animal would have the same N-terminal sequence as the plasmin of that animal.

Quite surprisingly, native angiostatin has been found to have its C-terminal amino acid located in kringle 5. In particular, angiostatin produced from human plasminogen has been found to have the C-terminal sequence Cys Tyr Thr Thr Asn Pro Arg [SEQ ID NO:4] or Cys Tyr Thr Thr Asn Pro Arg Lys [SEQ ID NO:5] (see Example 6). These C-terminal sequences would result from a cleavage after amino acid 529 or 530 of plasminogen (see Figure 16), which are known plasmin cleavage sites. Thus, native human angiostatin comprises most of kringle 5 (see Figure 16), which is consistent with its molecular weight of 50-60 kD on polyacrylamide gel electrophoresis under non-reducing conditions.

These findings were surprising because it had been thought that angiostatin contained kringles 1-3 and part or all of kringle 4 (see Background section). Also, it has been shown that a molecule consisting of kringles 1-4, while active, was less active than a molecule consisting of kringles 1-3 (see PCT application WO 96/35774). Thus, it was unanticipated that native angiostatin would include any portion of kringle 5. It was particularly unanticipated that native angiostatin would include most of kringle 5.

It is now expected that plasminogen fragments, other than native angiostatin, including at least a portion of kringle 5 will possess angiostatin activity (*i.e.*, will inhibit angiogenesis). Preferably the plasminogen fragment comprises the majority of kringle 5. More preferably the plasminogen fragment comprises most of kringle 5. As used herein "majority of kringle 5" means at least 50% of kringle 5 (*e.g.*, at least 40 amino acids for human kringle 5), and "most of kringle 5" means at least 75% of kringle 5 (*e.g.*, at least 60 amino acids for human kringle 5). Of course, the plasminogen fragment is most preferably native angiostatin for the reasons given above.

The sequences of plasminogens from other animals are known (available from, *e.g.*, GenBank). The sequences of human [SEQ ID NO:6], bovine [SEQ ID NO:7], canine [SEQ ID NO:8], western European hedgehog [SEQ ID NO:9], horse [SEQ ID NO:10], rhesus monkey [SEQ ID NO:11], mouse [SEQ ID NO:12], and pig [SEQ ID NO:13] plasminogen are given below in the Sequence Listing (downloaded from SWISS-PROT Protein Sequence Database). Native angiostatin for a particular animal would include most of kringle 5 of that animal's plasminogen and would have a C-terminal sequence corresponding to the C-terminal sequences of human native angiostatin given above. Indeed, a review of these sequences showed that the sequence immediately after the cleavage sites in human plasminogen that produce native angiostatin (SEQ ID NO:2 and SEQ ID NO:3; see Example 6 below) is conserved in all of these plasminogen sequences (see the amino acids highlighted in bold in the Sequence Listing).

As can be observed from the Sequence Listing, the sequences of canine [SEQ ID NO:8] and horse [SEQ ID NO:10] plasminogens contain only a single kringle domain. This

single kringle domain is considered a kringle 5 domain by homology to other kringle 5 domains, and it contains the conserved sequence (see highlighted amino acids in the Sequence Listing) found in the kringle 5 domains of the other plasminogens. Thus, the invention includes plasminogen fragments of canine and horse plasminogens and of any other plasminogen containing a kringle 5 domain.

Plasminogen fragments of the invention (those having the N-terminal sequence of plasmin and having their C-terminal amino acids located in kringle 5) can be produced by recombinant DNA methods. Preferably the plasminogen fragment is native angiostatin. Most preferably the plasminogen fragment is native human angiostatin. Recombinant DNA methods and suitable host cells, vectors and other reagents for use therein, are well known in the art.

The selection of a particular host cell for production of a plasminogen fragment of the invention is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the plasminogen fragment to the cell, rate of transformation, expression characteristics, bio-safety, and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular plasminogen fragment.

Eukaryotic host cells are preferred for making the plasminogen fragments of the invention. Within the above guidelines, useful eukaryotic host cells include yeast and other fungi, animal cell lines, animal cells in an intact animal, insect cells, and other eukaryotic host cells known in the art.

The host cells may be transformed with a vector comprising DNA encoding a plasminogen fragment of the invention. On the vector, the coding sequence must be operatively linked to expression control sequences.

As used herein "operatively linked" refers to the linking of DNA sequences in such a manner that the plasminogen fragment will be expressed. Preferably the linking, including the order of the sequences, the orientation of the sequences, and the relative spacing of the various sequences, is performed so that optimum expression is obtained.



The expression control sequences must include a promoter. The promoter used in the vector may be any sequence which shows transcriptional activity in the host cell and may be derived from genes encoding homologous or heterologous proteins and either extracellular or intracellular proteins. However, the promoter need not be identical to any naturally-occurring promoter. It may be composed of portions of various promoters or may be partially or totally synthetic. Guidance for the design of promoters is provided by studies of promoter structure such as that of Harley and Reynolds, Nucleic Acids Res., 15, 2343-61 (1987). Also, the location of the promoter relative to the transcription start may be optimized. See Roberts, et al., Proc. Natl Acad. Sci. USA, 76, 760-4 (1979). The promoter may be inducible or constitutive, and is preferably a strong promoter. By "strong," it is meant that the promoter provides for a high rate of transcription in the host cell.

In the vector, the coding sequences must be operatively linked to transcription termination sequences, as well as to the promoter. The coding sequence may also be operatively linked to expression control sequences other than the promoters and transcription termination sequences. These additional expression control sequences include activators, enhancers, operators, stop signals, cap signals, polyadenylation signals, 5' untranslated sequences, and other sequences and signals involved with the control of transcription or translation.

The consensus sequence for the translation start sequence of eukaryotes has been defined by Kozak (Cell, 44, 283-292 (1986)) to be: C(A/G)CCAUGG. Deviations from this sequence, particularly at the -3 position (A or G), have a large effect on translation of a particular mRNA. Virtually all highly expressed mammalian genes use this sequence. Highly expressed yeast mRNAs, on the other hand, differ from this sequence and instead use the sequence (A/Y)A(A/U)AAUGUCU (Cigan and Donahue, Gene, 59, 1-18 (1987)). These sequences may be altered empirically to determine the optimal sequence for use in a particular host cell.

DNA coding for a plasminogen fragment of the invention may prepared using standard methods such as those described in Maniatis et al., *Molecular Cloning: A*

*Laboratory Manual*, Cold Spring Harbor, NY (1982), Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, NY (1989). In particular, clones coding for plasminogen are known. See, e.g., GenBank PCT application WO 95/29242; Browne et al., *Fibrinolysis*, **5**, 257-260 (1991). Other clones may be identified by methods known in the art. The clones, whether known or newly-identified, may be modified to code for a plasminogen fragment of the invention by methods known in the art.

The coding sequences may, alternatively, be synthesized using standard techniques that are well known in the art using the known plasminogen sequences. For instance, DNA sequences may be synthesized by phosphoramidite chemistry in an automated DNA synthesizer, purified, annealed, ligated and cloned into suitable vectors. Chemical synthesis is preferable for several reasons.

First, chemical synthesis is desirable because codons preferred by the host in which the DNA sequence will be expressed may be used to optimize expression. Not all of the codons need to be altered to obtain improved expression, but greater than 50%, most preferably at least about 80%, of the codons should be changed to host-preferred codons. The codon preferences of many host cells are known. See Maximizing Gene Expression, pages 225-85 (Reznikoff & Gold, eds., 1986). The codon preferences of other host cells can be deduced by methods known in the art.

The use of chemically synthesized DNA also allows for the selection of codons with a view to providing unique or nearly unique restriction sites at convenient points in the sequence. The use of these sites provides a convenient means of constructing the synthetic coding sequences. In addition, if secondary structures formed by the messenger RNA transcript or other destabilizing sequences interfere with transcription or translation, they may be eliminated by altering the codon selections.

Chemical synthesis also allows for the use of optimized expression control sequences with the DNA sequence coding for a plasminogen fragment. In this manner, optimal expression of the plasminogen fragments can be obtained. For instance, as noted above,

promoters can be chemically synthesized and their location relative to the transcription start optimized.

DNA coding for a signal or signal-leader sequence may be located upstream of the DNA sequence encoding the plasminogen fragment. A signal or signal-leader sequence is an amino acid sequence at the amino terminus of a protein which allows the protein to which it is attached to be secreted from the cell in which it is produced. Suitable signal and signal-leader sequences are well known. Although secreted proteins are often easier to purify, expression levels are generally lower than those that can be obtained in the absence of secretion.

Vectors for expressing the plasminogen fragments may be any vector which may conveniently be subjected to recombinant DNA procedures and which is capable of expressing a plasminogen fragment in the selected host cell. The vector used to transform the host cells may have one or more replication systems which allow it to replicate in the host cells. In particular, when the host is a yeast, the vector should contain the yeast 2u replication genes REP 1-3 and origin of replication.

Alternatively, an integrating vector may be used which allows the integration into the host cell's chromosome of the sequence coding for a plasminogen fragment of the invention. Although the copy number of the coding sequence in the host cells would be lower than when self-replicating vectors are used, transformants having sequences integrated into their chromosomes are generally quite stable.

When the vector is a self-replicating vector, it is preferably a high copy number plasmid so that high levels of expression are obtained. As used herein, a "high copy number plasmid" is one which is present at about 100 copies or more per cell. Many suitable high copy number plasmids are known.

The vector desirably also has unique restriction sites for the insertion of DNA sequences and a sequence coding for a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host cell ("a selection marker"). If a vector does

not have unique restriction sites, it may be modified to introduce or eliminate restriction sites to make it more suitable for further manipulations.

After the vector comprising a DNA sequence coding for a plasminogen fragment of the invention is prepared, it is used to transform the host cells. Methods of transforming host cells are well known in the art, and any of these methods may be used.

Transformed host cells are selected in known ways and then cultured under conditions effective to produce the plasminogen fragment. The methods of culture are those well known in the art for the chosen host cell.

The expressed plasminogen fragment may be recovered using methods of recovering and purifying proteins from recombinant cell cultures which are well known in the art. In particular, antibodies which bind selectively to the plasminogen fragments of the invention may be used to purify the fragments (see below).

The invention also provides methods of treating an angiogenic disease. An angiogenic disease is one caused by, involving or dependent on angiogenesis. Angiogenic diseases include neoplastic diseases (*e.g.*, tumors and tumor metastasis), benign tumors (*e.g.*, hemangiomas, acoustic neuromas, neurofibromas, trachomas, pyrogenic granulomas), connective tissue disorders (*e.g.*, rheumatoid arthritis and atherosclerosis), ocular angiogenic diseases (*e.g.*, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis), cardiovascular diseases, cerebral vascular diseases, diabetes-associated diseases and immune disorders (*e.g.*, chronic inflammation and autoimmunity).

The angiogenic disease may be treated by administering an effective amount of native angiostatin or of another plasminogen fragment having the N-terminal sequence of plasmin and containing at least a portion of kringle 5. Native angiostatin is preferred for the reasons given above.

The angiogenic disease may also be treated by administering an amount of a sulfhydryl donor sufficient to cause conversion of plasmin to angiostatin. An effective amount of a plasminogen activator may also be administered to the animal to produce

plasmin from plasminogen. The plasminogen or plasmin may be those found endogenously in the animal or effective amounts of plasminogen or plasmin are also administered to the animal.

In addition, the angiogenic disease may be treated by administering an amount of a plasminogen activator sufficient to cause conversion of plasminogen to plasmin. the plasminogen may be that found endogenously or an effective amount of plasminogen may also be administered to the animal. The plasmin is converted to angiostatin by a sulfhydryl donor. The sulfhydryl donor may be one found endogenously in the animal or an effective amounts of sulfhydryl donor can also be administered to the animal. One example of an endogenous free sulfhydryl donor which can facilitate conversion of plasmin to angiostatin is glutathione. Glutathione is a well-known endogenous chemical, present in normal and cancer tissues, which is released by the cells into the extracellular environment. In this extracellular environment, glutathione may serve as a free sulfhydryl donor to mediate conversion of plasmin to angiostatin. Melloni et al. demonstrated that the levels of glutathione in epithelial lining fluid (ELF), obtained by bronchoalveolar lavage, was significantly greater from patients with lung cancer (1,485.5 +/- 208  $\mu$ M) when compared with smokers (544 +/- 97.6  $\mu$ M) and nonsmokers (339.3 +/- 112  $\mu$ M) without cancer ( $p < 0.05$ ) (Melloni et al., *Am. J. Respir. Crit. Care Med.*, **154** (6 Pt 1): 1706-11, 1996.). Of note, as shown by Soff and colleagues, 100  $\mu$ M levels of glutathione can serve as a cofactor for angiostatin generation, supporting the paradigm that endogenous levels of glutathione or other free sulfhydryl donors can be sufficient to convert endogenous plasmin to angiostatin (Gately et al., *Proc. Natl. Acad. Sci. USA*, **94** (20): 10868-72, 1997).

Any animal suffering from an angiogenic disease can be treated. Suitable animals treatable according to the invention include mammals, such as dogs, cats, horses, other domestic animals, and humans.

Effective dosage forms, modes of administration and dosage amounts for the various compounds for treating angiogenic diseases may be determined empirically, and making such determinations is within the skill of the art. It is understood by those skilled in the art that

the dosage amount will vary with the activity of the particular compound employed, the severity of the angiogenic disease, the route of administration, the rate of excretion of the compound, the duration of the treatment, the identify of any other drugs being administered to the animal, the age, size and species of the animal, and like factors known in the medical and veterinary arts. In general, a suitable daily dose of a compound of the present invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. However, the daily dosage will be determined by an attending physician or veterinarian within the scope of sound medical judgment. If desired, the effective daily dose may be administered as two, three, four, five, six or more sub-doses, administered separately at appropriate intervals throughout the day.

The compounds of the present invention may be administered to an animal patient for therapy by any suitable route of administration, including orally, nasally, rectally, vaginally, parenterally (*e.g.*, intravenously, intraspinally, intraperitoneally, subcutaneously, or intramuscularly), intracisternally, transdermally, intracranially, intracerebrally, and topically (including buccally and sublingually). The preferred routes of administration are subcutaneous, orally and intravenously. The use of biodegradable polymers similar to that described by Brem, et al., *Lancet*, **345**, 1571 (1995) for the local sustained release of pharmacological agents following incorporation into the biodegradable polymers is also a preferred method of administration. Implantation of the drug-impregnated polymer at, *e.g.*, a tumor site, allows prolonged local exposure with minimal systemic exposure.

While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition). The pharmaceutical compositions of the invention comprise a compound of the invention as an active ingredient in admixture with one or more pharmaceutically-acceptable carriers and, optionally, with one or more other compounds, drugs or other materials. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

Pharmaceutical formulations of the present invention include those suitable for oral, nasal, ophthalmic, topical, rectal, vaginal and/or parenteral administration. Regardless of the route of administration selected, the compounds of the present invention are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.

The amount of active ingredient which will be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration and all of the other factors described above. The amount of active ingredient which will be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which is the lowest dose effective to produce a therapeutic effect or the maximally-tolerated dose that yields a therapeutic increment for life-threatening illnesses, such as cancer.

Methods of preparing pharmaceutical formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, powders, granules or as a solution or a suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsions, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as bolus, electuary or paste.

In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or

any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient only,



or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in microencapsulated form.

Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound. Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any buffers, or propellants which may be required.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

Transdermal patches have the added advantage of providing controlled delivery of a compound of the invention to the body. Such dosage forms can be made by dissolving, dispersing or otherwise incorporating a compound of the invention in a proper medium, such as an elastomeric matrix material. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.

Pharmaceutical compositions of this invention suitable for parenteral administrations comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like in the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue. The injectable materials can be sterilized for example, by filtration through a bacterial-retaining filter.

The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a lyophilized condition requiring only the

addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the type described above.

An angiogenic disease can also be treated by gene therapy. In particular, a transgene comprising DNA coding for a plasminogen fragment having the N-terminal sequence of plasmin and containing at least a portion of kringle 5 operatively linked to expression control sequences is administered to an animal suffering from such a disease. Preferably the plasminogen fragment coded for by the transgene is native angiostatin. The preparation of DNA coding for the plasminogen fragments of the invention, including native angiostatin, operatively linked to expression control sequences is described above. Expression of the transgene in the animal results in the production of the plasminogen fragment, which inhibits angiogenesis in the animal.

Methods and materials for gene therapy are well known in the art. See Culver, *Gene Therapy: A Primer for Physicians* (Revised 2nd ed., 1996), U.S. Patents Nos. 5,521,291, 5,460,831 and 5,559,099, PCT applications WO 95/29242, WO 96/14876, and WO 96/35774, all of which are incorporated herein by reference in their entirety. See also, Kirshenbaum, et al., *J. Clin. Invest.*, **92**, 381-387 (1993) and Drazner et al., *J. Clin. Invest.*, **99**, 288-296 (1997). In particular, suitable methods and vehicles for delivery of transgenes are known and may be used to deliver the transgenes of the invention.

For instance, the transgene can be transfected into desired cells *in vitro*, and the transformed cells injected into an animal suffering from an angiogenic disease, preferably after expansion of the number of transformed cells. Methods of transfecting a transgene into cells *in vitro* are well known and include electroporation, direct injection of naked DNA into cells, particle bombardment, delivery by liposomes or other lipid-based carriers, delivery by viral vectors, etc.

Alternatively, the transgene can be administered to the animal in such a manner that it transforms cells within the animal. Methods of delivering transgenes *in vivo* are also well known and include direct injection of naked DNA into desired tissues, organs, or tumors, use

of liposomes and other lipid-based carriers to deliver the transgene, use of a noninfectious viral vector (e.g., a replication-deficient adenoviral vector) to deliver the transgene, use of targeted vehicles (a vehicle that allows the vehicle to bind to, and deliver the transgene to, a specific cell, tissue, organ or tumor such as liposomes having a tumor-specific antibody attached to them) to deliver the transgene, etc.

The invention also provides antibodies which bind selectively to a plasminogen fragment of the invention, including antibodies which bind selectively to native angiostatin. "Binds selectively" means that the antibody binds to a plasminogen fragment of the invention, such as native angiostatin, in preference to plasminogen or plasmin.

Antibodies coming within the scope of the invention include polyclonal antibodies, affinity-purified antisera, monoclonal antibodies, fragments of antibodies (such as Fab, F(ab') or F(ab')<sub>2</sub>) that are capable of binding antigen, any known isotype or subclass of antibody, and engineered antibodies (such a single-chain antibody prepared by recombinant DNA techniques). The only requirements are that the final antibody preparation have specificity for the plasminogen fragment and be capable of binding selectively to the fragment.

Methods of making antibodies and fragments of antibodies are well known in the art. For instance, the antibodies of the present invention may be prepared by injecting a suitable host animal (such as a rabbit, goat, horse or other mammal) with a plasminogen fragment of the invention in admixture with an adjuvant. The injections of the fragment are continued until an antiserum of suitable titer is obtained. The antiserum is harvested and may be further purified using known techniques if needed or desired. For instance, the antibodies may be affinity purified or may be fractionated such as by DE-52 chromatography.

Preferably, however, the antibodies of the invention are prepared by somatic cell hybridization by fusing cells from an immunized animal (such as rats, hamsters, mice or other mammal) with an immortal cell line such as myeloma cells. The fused cells are cloned, and monoclonal antibodies of appropriate specificity can be isolated by screening the cloned fused cells. Techniques of preparing monoclonal antibodies are well-known.

Antibodies which bind selectively to a plasminogen fragment of the invention can be used to purify the plasminogen fragments from fluids containing them. Such fluids include culture media, such as those resulting from practice of the methods of the invention for producing native angiostatin and the plasminogen fragments of the invention (see above). Native angiostatin would be found, in addition, in body fluids (*e.g.*, blood, plasma, serum, saliva, urine and fluids produced by tumors).

To purify a plasminogen fragment, the fluid containing it is contacted with an antibody specific for the particular fragment. Preferably, the antibody is attached to a solid surface before being contacted with the fluid containing the fragment. Suitable solid surfaces are well known in the art and are available commercially. Examples include glass, polyacrylamide, polymethylmethacrylate, polycarbonate, polyacrylonitrile, polyethylene, polypropylene, polystyrene, latex beads, agarose beads, and nylon.

The antibody is preferably attached covalently to the solid surface. Methods and agents for attaching antibodies covalently to solid surfaces are well known in the art. Suitable agents include carbodiimide, cyanoborohydride, diimidoesters, periodate, alkylhalides, succinimides, dimethylpimelimidate and dimaleimides. See Blair et al., *J. Immunol. Methods*, **59**, 129 (1993); Blair et al., *Cancer Res.*, **41**, 2700 (1981); Gauthier et al., *J. Expr. Med.*, **156**, 766 (1982).

The specific concentrations of reactants, the temperature and time of incubation, as well as other conditions for obtaining binding of the antibody to the plasminogen fragment, can be varied depending on such factors as the concentration of the plasminogen fragment in the fluid, the nature of the fluid and the like. Those skilled in the art will be able to determine operative and optimal conditions while employing routine experimentation.

After the antibody has bound to the plasminogen fragment, the remainder of the fluid is separated from the bound plasminogen fragment. The plasminogen fragment is then released from the antibody by known methods.

Most preferably, a solid surface with the antibody attached to it is located in a column. For instance, a column filled with agarose beads having antibody attached to them.

The fluid containing the plasminogen fragments is simply passed through the column, and the plasminogen fragments in the fluid bind to the antibody in the column and are retained in the column, while the remainder of the fluid passes through the column. After the column is washed, the plasminogen fragments are released from the antibody.

Antibodies of the invention which bind selectively to native angiostatin can also be used to detect or quantitate native angiostatin for the diagnosis of an angiogenic disease or to monitor for the recurrence of such a disease. Such antibodies can also be used to study the mechanism of action of angiostatin in the body.

Native angiostatin may be detected in materials such as body fluids (see above), cells and tissues (tumor tissue, placenta, uterus, brain, liver and intestines). Native angiostatin may be released from the cells or tissues by known extraction techniques, or intact cells or tissue sections may be used.

The native angiostatin in fluids or extracts can be detected or quantitated using conventional immunoassay techniques. Such techniques include agglutination, radioimmunoassay, enzyme immunoassays, fluorescence assays, colorimetric assays, etc. The immunoassay may be performed in the competitive binding format or may be an immunometric assay. It may be a homogenous or heterogenous assay. Suitable homogenous techniques are fluorescence quenching and enhancement, energy transfer immunoassay, double antibody steric hinderance immunoassay, substrate-labeled immunoassay, prosthetic group-labeled immunoassay and enzyme modulator-labeled immunoassay.

The native angiostatin on cells or tissues can be detected by standard immunohistochemical techniques well known in the art. For example, tumors are biopsied or collected, and tissue sections cut with a microtome to examine sites of native angiostatin production. Such information is useful for diagnostic and possibly therapeutic purposes in the detection and treatment of cancer and is useful for research purposes for studying the mode of action of angiostatin.

The native angiostatin can be detected or quantified using a labeled antibody which binds selectively to native angiostatin (primary antibody) or a labeled component that binds

to immunoglobulin, such as another antibody (secondary antibody) or protein A. Suitable labels for either the primary antibody or for the component which binds to the primary antibody are well-known in the art. They include: 1) enzymes (*e.g.*, horseradish peroxidase, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholine esterase); 2) fluorophores (such as fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine), 3) radionucleotides (such as  $^{125}\text{I}$ ); 4) bioluminescent labels (such as luciferin, luciferase and aequorin); 5) chemiluminescent labels (such as luminol, isoluminol, aromatic acridinium ester, imidazole, acridinium salt and oxalate ester); 6) particulate labels (such as gold nanoparticles); and 7) biotin/avidin or biotin/streptavidin. The binding and detection of these labels can be performed using standard techniques known to those skilled in the art.

The specific concentrations of reactants, the temperature and time of incubation, as well as other conditions, can be varied in whatever immunoassay or immunohistochemical technique is employed, depending on such factors as the concentration of the native angiostatin in the sample, the nature of the sample and the like. Those skilled in the art will be able to determine operative and optimal conditions for each determination while employing routine experimentation.

A test kit for detecting or quantitating native angiostatin is also part of the invention. The kit is a packaged combination of one or more containers holding reagents useful in performing the immunoassays or immunohistochemical techniques of the invention. Suitable containers for the reagents of the kit include bottles, vials, test tubes, microtiter plates, dipsticks, strips, and other solid surfaces.

The kit will comprise a container of an antibody which binds selectively to native angiostatin. These antibodies are those described above. The antibody may be in solution,



may be lyophilized, or attached to a solid surface, and may be labeled or unlabeled. The solid surfaces are the types described above, and the antibody is attached as described above.

The kit may further comprise a container holding the above-described labeled component that binds to the primary antibody. The labels are those described above.

Finally, the kit may also contain other materials which are known in the art and which may be desirable from a commercial and user standpoint. Such materials may include a sample of native angiostatin (for standardizing immunoassays or for binding to cells or tissues in immunohistochemical techniques), buffers, enzyme substrates, diluents, and equipment for performing the immunoassay or immunohistochemical technique.

## EXAMPLES

### Example 1: Preparation of Conditioned Medium Containing Plasminogen-Angiostatin Converting Activity (PACA)

This example demonstrates that a variety of cells express enzymatic activity that can generate bioactive angiostatin from purified human plasminogen or plasmin. Affinity-purified angiostatin generated by incubating plasminogen or plasmin with serum-free conditioned medium (SFCM) inhibited human endothelial cell proliferation, migration induced by angiogenic factor basic fibroblast growth factor (bFGF), endothelial cell tube formation, and bFGF-induced corneal angiogenesis. Serine proteinase inhibitors, but not inhibitors of metallo-, cysteine, or aspartic proteinases, blocked angiostatin generation. Elastatinal, a specific inhibitor of elastase, failed to block angiostatin generation, indicating that an elastase is not responsible for the conversion of plasminogen to angiostatin. Instead, the data show that serine proteinase activity is necessary for angiostatin generation.

#### A. Methods

1. Cell Culture. The human umbilical vein endothelial cells (HUVEC), were grown in RPMI supplemented with 20% bovine calf serum (Hyclone Laboratories Inc., Logan Utah #A-2151-L), 100 U/ml penicillin G, 100 mg/ml streptomycin, L-glutamine,

(Gibco BRL), 2500 U Sodium heparin (Fisher Scientific, Itasca, IL), and 50 mg/ml endothelial cell growth supplement (Collaborative Biomedical Research, Bedford, MA). The other cells listed in Table 1 were grown in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin G, 100 mg/ml streptomycin (Gibco BRL, Gaithersburg, MD). Cells were maintained at 37°C in a humidified incubator in an atmosphere of 5% CO<sub>2</sub>. To generate SFCM, confluent cell monolayers were washed twice with phosphate buffered saline, then serum-free RPMI was added. The next day the SFCM was collected and centrifuged at 3000 rpm for 15 minutes to remove insoluble cellular debris.

2. Angiostatin Generation. Two micrograms of human plasminogen, obtained by lysine-sepharose affinity chromatography of human plasma (Castellino & Powell, *Methods Enzymol*, **80**, 365-78 (1981)), or human plasmin (#527624, Calbiochem-Novabiochem Corp., La Jolla, CA) were added to 100 µl aliquots of SFCM and the mixture incubated at 37°C overnight. Aliquots were analyzed for angiostatin generation by western blot (see below). Plasminogen cleavage by SFCM was also assessed in the presence of proteinase inhibitors (Boehringer Mannheim, Indianapolis, IN).

3. Western Blot. Samples were electrophoresed under non-reducing conditions on 12% polyacrylamide gels (NOVEX, San Diego, CA) in Tris-Glycine running buffer (Laemmli, *Nature*, **227**, 680-685 (1970)), and electrotransferred to a 0.45 µM polyvinylene difluoride (PVDF) membrane (Immobilon, Millipore, Bedford, M.A.). The membrane was then blocked for 30 minutes in blocking buffer (1% bovine serum albumin in Tris-buffered saline) and probed with a 1:1000 dilution of a monoclonal antibody to the kringle 1-3 (K1-3) fragment of human plasminogen (VAP 230L, Enzyme Research Laboratories, Inc., South Bend, IN). Following washing, the membrane was incubated for 30 minutes with an alkaline phosphatase conjugated goat anti-mouse IgG secondary antibody (Kirkegaard & Perry Laboratories (KPL), Gaithersburg, MD) and developed using 5-bromo-4-chloro-3-indoyl-phosphate/nitroblue tetrazolium (KPL).

4. Zymographic Analysis. Zymograms to detect matrix metalloproteinase activity were performed as described previously. Heussen & Dowdle, *Anal. Biochem.*, **102**, 196-202 (1980).

5. Chromogenic Peptide Substrates. To determine if an elastase was present, 50  $\mu$ l of SFCM were incubated with 0.3 mM of chromogenic peptide substrates specific for elastase (substrate I, MeOSuc-Ala-Ala-Pro-Val-pNA, SEQ ID NO:15; substrate II, Boc-Ala-Ala-Pro-Ala-pNA, SEQ ID NO:16); substrate III, pGlu-Pro-Val-pNA; substrate IV, Suc-Ala-Ala-Pro-Abu-pNA) (Calbiochem-Novabiochem Corp.), at 37°C for 2-18 hours. Substrate cleavage was determined by monitoring the absorbance at 405 nm (Molecular Devices, Menlo Park, CA).

6. Lysine-Sepharose Purification of Angiostatin. To generate purified angiostatin for bioactivity analyses, human plasminogen was incubated with PC-3 SFCM at 20  $\mu$ g/ml overnight at 37°C. The reaction product was applied to a lysine-sepharose column (Pharmacia Biotech), pre-equilibrated with TBS (50 mM Tris, pH 7.5, and 150 mM NaCl). Following washes with TBS to remove non-specifically bound protein, angiostatin was eluted in 0.2 M epsilon aminocaproic acid (EACA) in TBS. The eluted fraction was dialyzed (molecular weight cut off 12,000-14,000) to phosphate buffered saline. To remove residual plasmin, the angiostatin was applied to a soybean trypsin inhibitor agarose (Sigma Chemical Co., St. Louis, MO) column, and the flow-through collected, filter-sterilized and stored at -80°C until used. Angiostatin was quantitated by measuring the absorbance at 280 nm, using an  $A^{1\%}_{1\text{cm}}$  of 8.0. Sottrup-Jensen et al., in *Progress in Chemical Fibrinolysis and Thrombolysis*, vol. 3, pages 191-209 (Davidson et al. eds. 1978). The purified angiostatin was also examined by Coomassie brilliant blue staining of polyacrylamide gels, and immunodetection by western blot. Elastase-generated angiostatin, purified from human plasma as described in O'Reilly, et al., *Nature Med.*, **2**, 689-692 (1996), was a generous gift from M.S. O'Reilly, Children's Hospital, Harvard University, Boston, MA.

7. Microsequence Analysis of Angiostatin. To determine the NH<sub>2</sub>-terminus of the angiostatin bands, 10  $\mu$ g/ml of the affinity-purified angiostatin prepared by incubating

plasminogen with PC-3 SFCM was electrophoresed on a 12% SDS-polyacrylamide gel, electroblotted to a PVDF membrane, and stained with Coomassie blue. The bands were excised, placed on Porton sample support discs, and sequenced using a pulse liquid-phase sequencer with phenylthiohydantoin analysis.

5           8.     Endothelial Cell proliferation Assay. Cell proliferation was determined utilizing the CellTiter 96™ AQ Non-Radioactive Cell Proliferation Assay (Promega Corp., Madison, WI). The human endothelial cells were plated in a 96-well tissue culture plates (Becton Dickinson, Lincoln Park, NJ) at a concentration of  $5.0 \times 10^3$  cells/well. The following day, 1, 5, 8, or 10 µg/ml of angiostatin in fresh medium was added to triplicate wells. Wells without angiostatin served as control. The cells were incubated for 72 hours, and an absorbance read at 490 nm, reflecting the number of proliferating cells, was measured using an automated microplate reader (Molecular Devices). The results are reported as the percent of non-treated control cell number.

10           9.     Endothelial Cell Migration Assay. To determine the ability of angiostatin prepared by incubation of plasminogen with PC-3 SFCM to block migration of endothelial cells towards an angiogenic factor, bFGF, migration assays were performed in a modified Boyden chamber using bovine capillary endothelial cells (a kind gift of Dr. Folkman, Harvard Medical School, Boston, MA) as described previously. Dameron et al., *Science*, **265**, 1582-84 (1994). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% donor calf serum and 100 mg/ml endothelial cell mitogen and used at passage 15. To assess migration, the cells were serum starved overnight in DMEM supplemented with 0.1% bovine serum albumin (BSA), harvested, suspended in DMEM/BSA, plated at  $10^6$ /ml on the lower surface of a gelatinized membrane (Nucleopore Corp., Pleasanton, CA) in an inverted Boyden chamber, and incubated for 1.5-2 hours to allow cell attachment. The chambers were reinverted, test material was added to the top well, and the chamber incubated for an additional 3-4 hours. Membranes were then fixed and stained and the number of cells that migrated to the top of the filter in 10 high-power fields was determined. DMEM with 0.1% BSA was used as a negative control, and bFGF (provided by Dr. Noel Bouck and

prepared as described in Dameron et al., *Science*, **265**, 1582-1584 (1994)) at 10 ng/ml was used as a positive control.

10. Endothelial Cell Tube Formation. HUVEC were plated on gels of Matrigel (kindly provided by Hynda Kleinman, National Institute of Dental Research) in 24-well tissue culture plates as described previously. Schnaper et al., *J. Cell. Physiol*, **156**, 235-246 (1993). Angiostatin, prepared by incubation with PC-3 SFCM, in non-conditioned RPMI was added to the wells, followed by cells at a final concentration of  $4.0 \times 10^4$  cells in 1 ml of 50% HUVEC culture medium, 50% RPMI. Each angiostatin or control condition was assayed in triplicate. The cultures were incubated for 16-18 hours at 37°C, in a 5% CO<sub>2</sub> humidified atmosphere, then fixed with Diff-Quick Solution II (Baxter, McGraw Park, IL). A representative area of the tube network was photographed using a Polaroid MicroCam camera at a final magnification of 35X. The photographs were then quantitated by a blinded observer who measured the length of each tube, correcting for portions of tubes that were incomplete. The total length of the tubes was determined for each photograph and the mean tube length was determined. The results were expressed as the mean  $\pm$  standard error of the mean.

11. Corneal Angiogenesis Assay. The corneal assay was performed as described previously. Polverini et al., *Methods Enzymol*, **198**, 440-450 (1991). Briefly, 5  $\mu$ l hydon pellets (Hydon Laboratories, New Brunswick, NJ) containing 10  $\mu$ g/ml bFGF or bFGF plus 1 or 10  $\mu$ g/ml angiostatin were implanted into the cornea of anesthetized rats. After 7 days, the animals were sacrificed and corneal vessels were stained with colloidal carbon and corneas were examined for angiogenic activity.

## B. Results

1. Angiostatin Generation By Conditioned Culture Medium. Incubation of human plasminogen with the SFCM produced by PC-3 cells resulted in the generation of multiple immunoreactive bands at approximately 50 kD (Fig. 1A), similar to those observed by O'Reilly et al. *Cell*, **79**, 315-328 (1994). Examination of SFCM from additional cell lines

also revealed the generation of the multiple bands, similar to the PC-3 SFCM (data not shown). These cell lines are listed in Table 1 below.

The initial indication that the product was angiostatin was based on the immunoreactivity with the monoclonal antibody specific for kringles 1-3 (K1-3) of plasminogen and the size of the cleavage product. Subsequent confirmation that the plasminogen cleavage product was bioactive angiostatin is described below.

Angiostatin generation by PC-3 SFCM was time-dependent. There was a significant decrease in the plasminogen substrate and a corresponding increase in angiostatin beginning at 3 hours, with complete conversion to angiostatin by 24 hours (Figure 1B). Dilution of the PC-3 SFCM resulted in a proportional decrease in angiostatin generation (Figures 1C and 1D).

To determine whether plasmin, the activated form of the zymogen plasminogen, could also be converted to angiostatin, plasmin was evaluated as a potential substrate. Incubation of plasmin with PC-3 SFCM yielded a product indistinguishable from the plasminogen-derived angiostatin (Figure 1A). In kinetic studies, plasmin was converted to angiostatin at a comparable rate to the plasminogen; 50% conversion by 8 hours, with complete conversion by 24 hours (data not shown). These data suggest that *in vitro* both plasminogen and plasmin are substrates from which angiostatin can be generated.

TABLE 1

Cell Lines Tested for Angiostatin-Generating Activity	
Human Prostate Carcinoma	Activity
PC-3	+++
DU-145	++
Ln-CaP	+
Human Breast Carcinoma	
MDA-MB-231	++
MCF-7	+/-
Human Glioma	
U-373	+
U-118	+
A-172	++
U-87	+
Mouse Melanoma	
B16F10	++
Bovine Smooth Muscle	
Primary cell line	++
Bovine Aortic Endothelial Cells	
BAEC	++

2. Enzymatic Class Of Plasminogen-Angiostatin Converting Activity. To determine the proteolytic class of the angiostatin generating activity, PC-3 SFCM was incubated with plasminogen in the presence of various proteinase inhibitors. The proteinase inhibitors were added to the SFCM/plasminogen mix prior to the overnight incubation. Samples were analyzed by western blot for evidence of inhibition of angiostatin generation.

Only serine proteinase inhibitors blocked angiostatin generation (see Table 2 below). By contrast none of the other classes of proteinase inhibitors were effective.

Angiostatin can be generated *in vitro* by limited proteolysis of plasminogen by elastase. Sottrup-Jensen et al. in *Progress in Chemical Fibrinolysis and Thrombolysis*, 3,

191-209 (Davidson et al. eds. 1978); O'Reilly et al., *Nature Med.*, **2**, 689-692 (1996); Dong et al., *Proc. Am. Assoc. Cancer Res.*, **37**, 58 (1996). In the present study, angiostatin generation was not inhibited by elastatinal, a specific inhibitor of elastase (see Table 2 below). Additionally, no elastase activity was detected in PC-3 SFCM based on co-  
 5 incubation of SFCM with 4 elastase-sensitive chromogenic substrates for 24 hours (data not shown). These data indicate that the human plasminogen-angiostatin converting activity is unlikely to depend on the action of an elastase. Furthermore, gelatin zymograms revealed no evidence of active or latent metalloproteinases in the PC-3 SFCM (not shown).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
21



TABLE 2

Proteinase Inhibitor	Concentration	Class	Inhibitory Activity *
Pefabloc	4.0 mM	Serine Proteinases	Complete
Aprotinin	0.3 $\mu$ M	Serine Proteinases	Complete
Soybean Trypsin Inhibitor	2.0 mM	Serine Proteinases	Complete
Benzamidine	1-10mM	Serine Proteinases	Weak
Elastatinal	50-100 $\mu$ M	Elastase	None
Antipain	100 $\mu$ M	Limited Serine Proteinases	None
Leupeptin	100 $\mu$ M	Serine and Thiol Proteinases	None
Chymostatin	100 $\mu$ M	Chymotrypsin	None
Bestatin	10 $\mu$ M	Aminopeptidases	Weak
E-64	10 $\mu$ M	Cysteine Proteinases	None
Pepstatin	1.0 $\mu$ M	Aspartic Proteinases	None
EDTA	1-10 mM	Metalloproteinases	None
1-10 Phenanthroline	10 $\mu$ M	Metalloproteinases	None
Phosphoramidon	100 $\mu$ M	Metalloproteinases	None

\* Complete inhibition is defined as no immunoreactive angiostatin bands; weak inhibition results in the development of faint angiostatin immunoreactive bands; and none refers to the full generation of angiostatin.

3. Purification Of Angiostatin. Angiostatin generated by PC-3 SFCM was affinity purified on lysine-sepharose (O'Reilly et al., *Nature Med.*, **2**, 689-692 (1996)), and the resulting product examined by western blot and Coomassie blue staining (Figure 2). The amino-terminal sequence of all three bands was KVYLSECKTG [SEQ. ID NO:1] that corresponds to residues 78-87 of the plasminogen molecule, confirming that the product was an internal fragment of plasminogen.

4. Angiostatin Generated By PC-3 SFCM Inhibits Angiogenesis. Because angiogenesis represents a cascade of cellular processes that includes endothelial cell proliferation, migration, and tube formation, (Folkman & Shing, *J. Biol. Chem*, **267**, 10931-10934 (1992)), multiple *in vitro* and *in vivo* assays related to angiogenesis were utilized to confirm that the product generated by incubating plasminogen with PC-3 SFCM was bioactive angiostatin.

Affinity purified angiostatin generated by PC-3 SFCM inhibited human endothelial cell proliferation in a concentration-dependent manner, with significant inhibition observed at 10  $\mu\text{g/ml}$  ( $P < 0.05$ ) in comparison to the non-treated control cell proliferation (Figure 3A).

Angiostatin generated by PC-3 SFCM also inhibited the bFGF-induced migration of bovine capillary endothelial cells (Figure 3B) with an  $\text{ED}_{50}$  of 0.35  $\mu\text{g/ml}$ . The dose/response curve of angiostatin generated by PC-3 SFCM was indistinguishable from that of elastase-generated angiostatin. Inhibition of migration occurred at a 10-fold lower concentration than required to inhibit proliferation, a finding that has been reported for other inhibitors of angiogenesis. Takano et al., *Cancer Res.*, **54**, 2654-2660 (1994). This may be due to the fact that the proliferation assay, in contrast to the migration assay, was conducted in RPMI supplemented with 20% calf serum and endothelial cell growth supplement, and therefore contained multiple stimulatory factors.

Endothelial cell tube formation on Matrigel was significantly inhibited at 15  $\mu\text{g/ml}$  (Figures 4A and B); the mean length of tubes in non-treated control was  $674.5 \pm 54$  mm in comparison to angiostatin produced by PC-3 SFCM,  $287.7 \pm 47$  mm ( $P < 0.005$ ).

To determine the effect of angiostatin generated by PC-3 SFCM on corneal angiogenesis *in vivo*, its ability to block bFGF-induced angiogenesis in the corneal angiogenesis assay was tested. The bFGF pellet induced angiogenesis in 100% of implanted corneas (Figure 5A). In contrast, angiostatin at 10  $\mu\text{g/ml}$  completely inhibited the bFGF-induced angiogenic response in 3 of 3 animals (Figure 5B). At a lower dose of 1.0  $\mu\text{g/ml}$ , angiostatin completely blocked angiogenesis in 2 of 3 animals, with partial inhibition in the third animal.

Taken together, these data indicate that the angiostatin generated by the PC-3 SFCM is a potent inhibitor of both *in vitro* and *in vivo* angiogenesis.

**Example 2: Identification of Factors Responsible For Converting Plasminogen to Angiostatin**

The human prostate carcinoma cell line PC-3 was grown and PC-3 SFCM was prepared as described in Example 1. Angiostatin was generated by incubation with PC-3 SFCM or other materials identified below as described in Example 1. Western blots were performed as described in Example 1.

PC-3 SFCM was applied to a Reactive Red 120-Agarose column (Sigma Chemical Co.). The flow-through had no residual plasminogen-angiostatin generating activity (PACA) as demonstrated by western blot analysis (Figure 6). The bound material was eluted with 1 M KCl according to the manufacturer's protocol, then dialyzed to Tris-buffered saline (TBS, 20 mM Tris, pH 7.4, 100 mM NaCl), with a molecular cut-off of 6000-8000 Dalton. PACA was not detected in the dialyzed fraction (Figure 6). The observation that PACA was not detected in either the flow-through or the eluate led to the hypothesis that two or more factors are necessary to generate angiostatin from plasminogen or plasmin, and that the factors were separated by the Reactive Red 120-Agarose chromatography, with one or more factors being present in the eluate and one more factors being contained in the flow-through.

To test this hypothesis, the dialyzed eluate was recombined with the flow-through. The recombined materials were able to convert plasminogen into angiostatin. Supplementation of the eluate with fresh RPMI culture medium, as well as the Reactive Red 120-Agarose flow-through, restored the capacity of the eluate to generate angiostatin, suggesting that the necessary factor was a component of RPMI, and not a protein or other factor unique to the SFCM.

To further define the putative cofactor, the individual components of RPMI were evaluated for the ability to complement the Reactive Red 120-Agarose eluate. The cofactor was present in the RPMI amino acid mix (Figure 6).

To determine which amino acid was capable of restoring PACA to the Reactive Red 120-Agarose eluate, the 20 amino acids found in RPMI were tested individually. L-cysteine was the only amino acid capable of restoring PACA to the Reactive Red 120-Agarose eluate (data not shown).

Because the addition of L-cysteine to the Reactive Red 120-Agarose eluate restored angiostatin generating activity, it was hypothesized that the cofactor was a sulfhydryl donor. Pharmacological reducing agents, D-penicillamine and captopril were therefore examined for the ability to restore PACA to the Reactive Red 12-agarose eluate. Addition of 100  $\mu$ M D-penicillamine to the Reactive Red 120-Agarose eluate restored angiostatin generating activity. Captopril also restored angiostatin generating activity to the Reactive Red 120-Agarose eluate.

PC-3 SFCM was diluted to 50 mM Tris, pH 10.0, 20 mM NaCl and applied to a Hi-Q Sepharose anion exchange resin (Bio Rad). No PACA was detected in the flow-through.

Preliminary experiments indicated that PACA eluted from the Hi-Q Sepharose column with 300 mM NaCl. Therefore, the bound material was eluted utilizing a linear gradient from 20 mM to 300 mM NaCl. PACA and urokinase-type plasminogen activator (u-PA) activity were measured in the fractions (after dilution to restore physiological NaCl concentrations). The u-PA activity and PACA co-purified (Figure 7). Examination of the Reactive Red 120-Agarose eluate revealed it also contained u-PA.

As noted in Example 1, the  $\text{NH}_2$ -terminal cleavage of angiostatin is at Lys<sup>77</sup>, a site that results from cleavage of Glu-plasminogen by plasmin. This suggests that plasmin generation may be a necessary intermediate step in angiostatin generation from plasminogen.

To determine if the factor in the Reactive Red 120-Agarose eluate was u-PA, u-PA was tested as a substitute for the Reactive Red 120-Agarose eluate. As illustrated in Figure 8, u-PA was capable of generating angiostatin in the presence of boiled Reactive Red 120-Agarose flow-through or RPMI, both sources of sulfhydryl donors. This indicates that the only protein necessary for conversion of plasminogen to angiostatin is u-PA.

Next, u-PA, tissue-type plasminogen activator (t-PA), and streptokinase were tested in combination with the Reactive Red 120-Agarose flow-through for PACA. The plasminogen activators alone failed to generate angiostatin from plasminogen but, in the presence of the flow-through, angiostatin was produced (Figure 9). These data suggest that plasmin generation is an intermediate for angiostatin generation, and that angiostatin generation is not dependent on which plasminogen activator is present.

Example 3: Generation Of Angiostatin Using Plasminogen Activators And Sulfhydryl Donors

Having demonstrated that the only protein necessary for conversion of plasminogen to angiostatin is a plasminogen activator and that a sulfhydryl donor is a necessary cofactor, it was next determined if these components are sufficient for angiostatin generation. All incubations were performed at 37°C for 18 hours in TBS, and the resulting samples were analyzed for angiostatin by Western blot (performed as described in Example 1).

Incubation of u-PA with plasminogen and at least 5  $\mu$ M reduced glutathione produced angiostatin (Figure 10). No angiostatin was produced in the absence of the glutathione.

Use of 100  $\mu$ M or 1 mM D-penicillamine in combination with u-PA was also capable of generating angiostatin (Figure 11).

Finally, incubation of plasminogen (0.2  $\mu$ M) with u-PA (0.2 nM), t-PA (1.0 nM), or streptokinase (8.0 nM) with 100  $\mu$ M N-acetyl-L-cysteine resulted in the production of angiostatin (Figure 12). Plasminogen was not converted to angiostatin in the absence of N-acetyl-L-cysteine.

These data show that plasminogen is converted to angiostatin by each of the classic plasminogen activators in the presence of a sulfhydryl donor, but not in the absence of the sulfhydryl donor. Further, these data and the data in Example 2 demonstrate that angiostatin is produced in the presence of physiological (L-cysteine, reduced glutathione) and pharmacological (captopril, D-penicillamine, N-acetyl-L-cysteine) reducing agents.

Example 4: Use Of Plasmin For Angiostatin Generation

Two micrograms of human plasminogen in 100  $\mu$ l of TBS was incubated with 10  $\mu$ l of uPA-Sepharose (Calbiochem, La Jolla, CA) for 2 hours at 37°C. Following this incubation, the sample was centrifuged to sediment the uPA-Sepharose, and the supernatant containing plasmin was collected. The complete conversion of plasminogen to plasmin was confirmed by analysis of the supernatant on Coomassie-stained reduced polyacrylamide gels. The purified plasmin was then incubated for 18 hours at 37°C with 100  $\mu$ M N-acetyl-L-cysteine, and samples analyzed for angiostatin generation by Western blot (performed as described in Example 1).

The results are shown in Figure 13. These results demonstrate that plasmin is a necessary intermediate in the generation of angiostatin from plasminogen, and that angiostatin can be produced by incubation of purified plasmin with a sulfhydryl donor.

Example 5: Treatment Of Tumors In Vivo With Sulfhydryl Donor, With And Without Plasminogen Activator

Eleven female beige nude mice (Taconic Labs, Germantown, NY) 6-8 weeks of age were injected subcutaneously in the right flank with  $1.0 \times 10^6$  murine hemangioendothelioma (EOMA) cells (generously provided by Dr. Robert Auerbach, Madison, WI) in 100  $\mu$ l phosphate-buffered saline. The EOMA tumor cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin G, and 100 mg/ml streptomycin (Life Technologies Inc., Gaithersburg, MD) and maintained at 37°C in a humidified incubator in an atmosphere of 10% CO<sub>2</sub>. The day of injection of the tumor cells was designated day 0.

Beginning on day 1, each of the mice was injected subcutaneously twice a day with the following:

TABLE 3

	<u>Group And Number Of Mice</u>	<u>Treatment</u>
5	Control (5)	Saline
	NAC (4)	N-acetyl-L-cysteine in saline (6 mg per injection)
10	uPA + NAC (4)	urokinase-type plasminogen activator in saline (250 Units per injection) + N-acetyl-L-cysteine in saline (6 mg per injection)

15 The size of the primary tumor in each mouse was measured three times weekly using tissue calipers, and tumor volume was determined using the formula ( $\text{width}^2 \times \text{length} \times 0.52$ ) (O'Reilly et al., *Nature Medicine*, **2**, 689-692 (1996)). The results are presented in Figure 14. As can be seen both treatment with NAC and treatment with uPA + NAC effectively and significantly decreased the mean tumor size as compared to the control group. It should be noted that one control mouse died on day 10 and another control mouse died on day 17. None of the mice treated with NAC or uPA + NAC died during the 21-day duration of the experiment.

20 Plasma samples taken from two of the control mice and three of the NAC-treated mice on the day of sacrifice were assayed for angiostatin by Western blot (performed as described in Example 1). As a control, two mice were injected subcutaneously with 1.00 mg of affinity-purified, cell-free angiostatin twice a day beginning on day 1 until 24 hours prior to sacrifice. Affinity-purified, cell-free angiostatin was generated as described in Example 3 and affinity purified on a lysine-sepharose column as described in Example 1. The results are shown in Figure 15. As can be seen, administration of NAC to the mice caused the production of angiostatin *in vivo* (Lanes 5, 6 and 7). No angiostatin production was detected in control mice (Lanes 1 and 2).

30

Example 6: Determination Of The C-Terminal Sequence Of Native Angiostatin

Native angiostatin was generated by incubating human plasminogen (0.2  $\mu$ M) with recombinant human u-PA (0.2 nM) (Abbott Laboratories, North Chicago, IL) and 100  $\mu$ M N-acetyl-L-cysteine at 37°C overnight. The material was then applied to a lysine-sepharose column (see Example 1), and the flow-through material was collected and concentrated. Aliquots of the concentrated flow-through material were electrophoresed under non-reducing conditions on 12% polyacrylamide gels (NOVEX, San Diego, CA) in Tris-Glycine running buffer, electrotransferred to a 0.45  $\mu$ m polyvinylene difluoride (PVDF) membrane (Immobilon, Millipore, Bedford, MA), and proteins stained with Coomassie blue.

The stained membrane showed two very prominent bands from the flow-through at approximately 30 kD. Although other bands were observed, the staining of these bands was considerably less than the staining of the two 30 kD bands, indicating that the two 30 kD bands contained the predominant constituents of the flow-through.

The N-terminal sequences of the proteins in the two 30 kD bands were determined by microsequence analysis as described in Example 1. The N-terminal sequence of the most prominent of the two bands was Lys Leu Tyr Asp Tyr Cys Asp Val [SEQ ID NO:2], while the sequence of the other band was Leu Tyr Asp Tyr Cys Asp Val [SEQ ID NO:3]. The location of these sequences in kringle 5 of plasminogen (see Figure 16) and the prominence of the two bands provided extremely strong evidence that these were the fragments released as a result of the cleavage of plasminogen to form the C-terminal of native angiostatin.

From the N-terminal sequences of the two 30 kD fragments, it was deduced that the C-terminal sequence of the native angiostatin was Cys Tyr Thr Thr Asn Pro Arg [SEQ ID NO:4] or Cys Tyr Thr Thr Asn Pro Arg Lys [SEQ ID NO:5]. These C-terminal sequences would be formed by cleavage after amino acid 529 (Arg) or 530 (Lys) of human plasminogen, which is in kringle 5 (see Figure 16), which are known plasmin cleavage sites. Cleavage at this point would give a plasminogen fragment of about the molecular weight observed for native angiostatin on polyacrylamide gel electrophoresis under non-reducing conditions (50-60 kD).



The N-terminal sequence of human native angiostatin [SEQ ID NO:1] is given above in Example 1. Thus, human native angiostatin was deduced to be a plasminogen fragment including most of kringle 5 with the N-terminal sequence

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly

5 [SEQ ID NO:1]

and the C-terminal sequence

Cys Tyr Thr Thr Asn Pro Arg [SEQ ID NO:4]

or

Cys Tyr Thr Thr Asn Pro Arg Lys [SEQ ID NO:5].

10

#### Example 7: Antibody To Native Angiostatin

An antibody to the C-terminal of native human angiostatin (see Example 6) was prepared by immunizing three New Zealand white rabbits with a peptide having the sequence:

15

Arg Asn Pro Asp Gly Asp Val Gly Gly

Pro Trp Cys Tyr Thr Thr Asn Pro Arg

[SEQ ID NO:17]

20

(purified by RP-HPLC to >95% purity; Multiple Peptide Systems, San Diego, CA) conjugated 1:1 (weight/weight) to Keyhole Limpet Hemocyanin (KLH) using glutaraldehyde as the cross-linking agent. The rabbits were immunized with the peptide-KLH conjugate, suspended in phosphate buffered saline and emulsified by mixing with an equal volume of complete Freund's Adjuvant, injected into four subcutaneous dorsal sites. Subsequent immunizations were performed using incomplete Freund's Adjuvant. The rabbits were bled from the auricular artery, the blood allowed to clot, and the serum collected by centrifugation. Affinity purification was carried out using the synthetic peptide [SEQ ID NO:17] coupled to agarose. Crude serum was applied to the resin and, after washes, the adsorbed protein was eluted with a low pH glycine-HCl buffer. The antiserum recognized

25

reduced and non-reduced plasminogen, plasmin and native angiostatin produced as described in Example 6, but not elastase-derived angiostatin (consisting of kringle 1-3).

#### Example 8: Treatment of Human Cancer Patients

Four human cancer patients were treated with a combination of a sulfhydryl donor and a plasminogen activator. Captopril was used as the sulfhydryl donor. Urokinase (uPA) or tissue plasminogen activator (tPA) was used as the plasminogen activator. The compounds administered and their doses and schedules of administration are summarized in Table 4 below. In addition, one of the patients (Case #2) received a single treatment with uPA alone (*i.e.*, without the captopril).

Blood samples, in sodium citrate anticoagulant, were taken before, and at various times after, treatment was begun. Platelet-poor plasma was isolated from the blood, and stored frozen until tested.

Western blots were performed on the plasma samples (diluted 1:20) in Tris-Buffered saline (20 mM Tris, pH 8.0, 150 mM NaCl) as described in Example 1. The results of the Western blots performed on some of the plasma samples taken from Case #2 are shown in Figure 17A. As noted above, this patient received uPA alone and in combination with captopril. As can be seen in Figure 17A, a marked increase in angiostatin levels was observed as a result of either treatment. This indicates that captopril, or other sulfhydryl donors, may not be necessary to convert plasmin to angiostatin in some situations. Such situations may include the presence of mesothelioma or other cancers that can release endogenous sulfhydryl donors or that, in some other way, mediate conversion of plasmin to angiostatin.

The lysine-binding proteins were purified from platelet-poor plasma samples obtained after the administration of uPA alone or uPA plus captopril to Case #2. First, 1 ml of platelet-poor plasma was diluted 1:40 with 20 mM Tris, pH 8.0, and incubated with 8 ml of Lysine-Sepharose (pre-equilibrated in 20 mM Tris, pH 8.0) for >12 hours with gentle shaking at 4°C. (In preliminary experiments, the 8:1 ratio of resin:plasma bound >99% of

angiostatin and plasma). The plasma supernatant was separated by gentle centrifugation (2000 x g), and the resin was washed 3 times with 40 ml of 100 mM NaCl, 20 mM Tris, 5mM EDTA, pH 8.0. After washing and repeat centrifugation, the bound proteins were eluted with 4 ml of 200 mM EACA, 20 mM Tris, 5 mM EDTA, pH 8.0, and the elution dialyzed to 40 mM NaCl, 20 mM Hepes, 5mM EDTA, pH 8.0, and spin concentrated (MW cutoff = 10,000) to 500 microliters. On Western blot and Coomassie-stained polyacrylamide gel electrophoresis, the lysine-binding fractions contained plasminogen, angiostatin, and complexed angiostatin only.

To evaluate the antiangiogenic activity of the lysine-binding fractions of the plasma samples taken from Case #2, a cellular proliferation assay was performed as follows. Bovine aortic endothelial cells were plated in 24-well culture dishes at  $1.0 \times 10^4$  cells/well in DMEM supplemented with 2.5 % heat-inactivated calf serum, 100 Units/ml penicillin G, 100 mg/ml streptomycin, and the cells were incubated overnight at 37°C in a humidified incubator. On each of the following three days, fresh medium containing 3 ng/ml human bFGF (R&D Systems, Minneapolis, MN) alone or with various amounts of the lysine-binding fractions was added. As a positive control, 100 nM affinity-purified, cell-free angiostatin (produced as described in Example 6) was used. After 72 hours of treatment, cells were washed with phosphate buffered saline, dispersed with trypsin-EDTA, and the cell number was determined by counting from duplicate wells using a Coulter counter. The results are shown in Figure 17B. As shown in that figure, administration of urokinase alone induced antiangiogenic activity as measured by this endothelial cell proliferation assay. While more antiangiogenic activity was induced by the administration of the combination of captopril and urokinase, the urokinase alone induced antiangiogenic activity. These data indicate that antiangiogenic activity is induced by plasminogen activators alone, although not as potently as by the plasminogen activators and free sulfhydryl donors in combination.

Case #1 was a 14 year old girl with recurrent Ewing's sarcoma of the left pelvis. After she could not tolerate chemotherapy or radiation therapy due to her extensive prior treatment, she received multiple cycles of the combination of captopril and urokinase. The

doses and schedules of administration are summarized in Table 4. For the first several  
 months, she received the captopril-urokinase combination for 3 consecutive days every 2  
 weeks. Subsequently, she received the combination 2 consecutive days every 3 weeks for  
 a total of one year. A “cycle” refers to the 2 or 3 days of treatment, plus the days off  
 5 treatment, until the therapy was begun again 2 or 3 weeks later. The Western blots revealed  
 generation of angiostatin-related protein, which included free angiostatin as well as a  
 complex of angiostatin with another protein or proteins. The other protein(s) has(have) not  
 yet been identified. The large immunoreactive bands observed on the Western blot are  
 believed to contain angiostatin because: (a) they cross-react with several antibodies to  
 10 angiostatin, including kringle-dependent antibodies and COOH-terminus specific antibodies;  
 (b) when affinity purified with lysine-Sepharose, and disulfide reduced, the complex yields  
 monomeric angiostatin; and (c) the complex can be affinity purified with a resin comprising  
 monoclonal antibodies to angiostatin coupled to Sepharose. Over three months of treatment,  
 the patient achieved a complete remission. The therapy was continued for a full year, and  
 15 the patient has remained in remission during the treatment period, as well as for 6 months  
 after completion of treatment.

All of the cases, their treatments, and the results achieved are summarized in Table  
 4.

Case No. 4228-1-1-1

Case	Disease	Angiostatic Cocktail (Drugs Administered)	Plasminogen Activator Doses	Captopril Doses	Schedule	Response
#1	Recurrent Ewing's sarcoma	uPA/Captopril	uPA, 500 U/kg bolus, 200 U/kg/hr for 6 hrs.	0.3 mg/kg/dose X 2 doses per day of treatment	3 Consecutive Days Every 3 Weeks	Complete Remission
#2	Mesothelioma	uPA/Captopril	uPA, intravenous (IV) bolus, 500 U/kg uPA, continuous infusion, 200 U/kg/hr for 6 hr.	18.75 mg/dose X 2 doses per day of treatment	3 Consecutive Days Every 2 Weeks	> 80% Tumor Regression
#3	Ovarian Cancer (Stage 4)	tPA/Captopril	tPA, IV bolus, 7 mg tPA, continuous infusion, 3 mg/hr for 6 hr.	25 mg/dose X 2 doses per day of treatment	3 Consecutive Days Every 2 Weeks	>50% Tumor Regression
#4	Hormone-Refractory, Metastatic Prostate Cancer	tPA/Captopril	tPA, IV bolus, 7.5 mg tPA, continuous infusion, 5 mg/hr for 6 hr.	25 mg/dose X 2 doses per day of treatment	Week 1: 5 consecutive days Week 2: 3 consecutive days Week 3: 3 days, every other day Week 4: 4 consecutive days Week 5: 1 day	>90% Decrease in prostate-specific antigen

WE CLAIM:

1. A method of generating angiostatin *in vitro* comprising contacting plasminogen with a plasminogen activator and a sulfhydryl donor.
2. The method of Claim 1 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase, and tissue plasminogen activator.
3. The method of Claim 1 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine, and reduced glutathione.
4. The method of Claim 1 wherein the angiostatin is at least partially purified from the reaction mixture.
5. The method of Claim 1 further comprising administering an effective amount of the angiostatin to an animal in need thereof.
6. The method of Claim 4 further comprising administering an effective amount of the angiostatin to an animal in need thereof.
7. A method of generating angiostatin *in vitro* comprising:  
contacting plasminogen with a plasminogen activator to produce plasmin; and  
contacting the plasmin with a sulfhydryl donor to produce the angiostatin.
8. The method of Claim 7 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase, and tissue plasminogen activator.
9. The method of Claim 7 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine, and reduced glutathione.
10. The method of Claim 7 wherein the plasmin is at least partially purified prior to contacting it with the sulfhydryl donor.
11. The method of Claim 7 wherein the angiostatin is at least partially purified from the reaction mixture.
12. The method of Claim 7 further comprising administering an effective amount of the angiostatin to an animal in need thereof.

13. The method of Claim 11 further comprising administering an effective amount of the angiostatin to an animal in need thereof.

14. A method of generating angiostatin *in vitro* comprising contacting plasmin with a sulfhydryl donor.

15. The method of Claim 14 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine, and reduced glutathione.

16. The method of Claim 14 wherein the angiostatin is at least partially purified from the reaction mixture.

17. The method of Claim 14 further comprising administering an effective amount of the angiostatin to an animal in need thereof.

18. The method of Claim 16 further comprising administering an effective amount of the angiostatin to an animal in need thereof.

19. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease an amount of a sulfhydryl donor effective to cause the conversion plasmin to angiostatin.

20. The method of Claim 19 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.

21. The method of Claim 19 wherein an effective amount of plasmin is also administered to the animal.

22. The method of Claim 19 further comprising administering an effective amount of a plasminogen activator to the animal to convert plasminogen to plasmin.

23. The method of Claim 22 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.

24. The method of Claim 22 wherein an effective amount of plasminogen is also administered to the animal.

25. A composition for generating angiostatin comprising a sulfhydryl donor and a plasminogen activator.

26. The composition of Claim 25 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.

27. The composition of Claim 25 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.

28. The composition of Claim 25 which is a conditioned culture medium produced by culturing cells capable of producing plasminogen activator in a culture medium or is a lysate of such cells.

29. A container holding a plasminogen activator, said container having a label thereon instructing administration of the plasminogen activator to an animal suffering from an angiogenic disease.

30. The container of Claim 29 further holding a sulfhydryl donor and said label on said container instructing administration of the combination of the sulfhydryl donor and plasminogen activator to an animal suffering from an angiogenic disease.

31. A container holding a sulfhydryl donor, said container having a label thereon instructing administration of the sulfhydryl donor to an animal suffering from an angiogenic disease in an amount effective to cause conversion of plasmin to angiostatin.

32. A method of generating angiostatin comprising:  
culturing cells capable of producing plasminogen activator in a culture medium for a time sufficient to produce conditioned culture medium (CCM) capable of converting plasminogen into angiostatin; and

contacting the CCM with plasminogen to produce the angiostatin.

33. The method of Claim 32 wherein the cells are selected from the group consisting of cancer cells, primary endothelial cells, smooth muscle cells and fibroblasts.

34. The method of Claim 32 wherein the angiostatin is at least partially purified from the CCM.



35. The method of Claim 32 further comprising administering the angiostatin to an animal in need thereof.

36. The method of Claim 34 further comprising administering the angiostatin to an animal in need thereof.

37. A method of generating angiostatin comprising:  
culturing and thereafter lysing cells capable of producing plasminogen activator; and

contacting the lysate with plasminogen to produce the angiostatin.

38. A protein having the following characteristics:

(a) it is a fragment of plasminogen;  
(b) its N-terminal amino acid is the same as the N-terminal amino acid of plasmin;

(c) its C-terminal amino acid is in kringle 5; and

(d) it inhibits angiogenesis.

39. The protein of Claim 38 which comprises at least 50% of kringle 5.

40. The protein of Claim 39 which comprises at least 75% of kringle 5.

41. The protein of Claim 38 which is a fragment of human plasminogen and which has the following additional characteristic:

(e) it has an approximate molecular weight of 50-60 kD on polyacrylamide gel electrophoresis under non-reducing conditions.

42. The protein of Claim 41 having the following additional characteristics:

(f) it has the N-terminal sequence:

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly

[SEQ ID NO:1]; and

(g) it has the C-terminal sequence:

Cys Tyr Thr Thr Asn Pro Arg [SEQ ID NO:4]; or

Cys Tyr Thr Thr Asn Pro Arg Lys [SEQ ID NO:5].

43. A DNA molecule comprising a sequence which codes for the protein of any one of Claims 38-42.

44. The DNA molecule of Claim 43 wherein the coding sequence is operatively linked to expression control sequences.

45. A host cell comprising the DNA molecule of Claim 44.

46. A method of producing a plasminogen fragment which inhibits angiogenesis comprising culturing the host cell of Claim 45.

47. An antibody which binds selectively to native angiostatin.

48. A method of detecting or quantitating native angiostatin in a material suspected of containing native angiostatin, the method comprising:

contacting the material with the antibody of Claim 47; and

detecting or quantitating any native angiostatin present in the material.

49. A kit for detecting or quantitating native angiostatin comprising a container holding the antibody of Claim 47.

50. An antibody which binds selectively to the protein of Claim 38.

51. A method of purifying a protein of Claim 38 from a material containing it, the method comprising:

contacting the material with the antibody of Claim 50 so that the antibody binds to the protein; and

separating the protein bound to the antibody from the remainder of the material.

52. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease an effective amount of the protein of any one of Claims 38-42.

53. The method of Claim 52 wherein the protein is native angiostatin.

54. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease a transgene comprising DNA coding for the protein of Claim 38 operatively linked to expression control sequences.

55. The method of Claim 54 wherein the protein coded for by the transgene is native angiostatin.

56. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease an amount of a plasminogen activator effective to cause the conversion plasminogen to plasmin.

57. The method of Claim 56 wherein an effective amount of plasminogen is also administered to the animal.

58. The method of Claim 56 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.

57

**ABSTRACT**

The invention provides methods of generating angiostatin *in vitro* comprising contacting plasminogen with a plasminogen activator and a sulfhydryl donor or contacting plasmin with a sulfhydryl donor. The invention also provides a method of treating angiogenic diseases by administering to an animal suffering from such a disease a sulfhydryl donor, a plasminogen activator, or a combination of a sulfhydryl donor and a plasminogen activator. The invention further comprises a composition for generating angiostatin comprising a sulfhydryl donor and a plasminogen activator. The invention also provides a container holding a sulfhydryl donor and/or a plasminogen activator, said container having a label thereon instructing administration of the sulfhydryl donor and/or plasminogen activator to an animal suffering from an angiogenic disease. The invention further provides plasminogen fragments whose N-terminal amino acid is the same as that of plasmin and whose C-terminal amino acid is located in kringle 5 and which inhibit angiogenesis, antibodies which bind selectively to these fragments, methods and kits for using the antibodies, methods and materials for making the fragments by recombinant DNA techniques, and a method of treating an angiogenic disease comprising administering an effective amount of one of the fragments. Finally, the invention provides a method of treating an angiogenic disease comprising administering a transgene coding for one of the fragments.




FIG.1A




FIG.1B





FIG.1C

FIG.1D






FIG.2

FIG.3A






FIG.3B




FIG.4A




FIG.4B




FIG.5A



FIG.5B






FIG.6





FIG.8

FIG.7






FIG.9




FIG.10




FIG.11




FIG.12




FIG.13

FIG.14





FIG.15








FIG.16




FIGURE 17A

Cell Number




FIGURE 17B

# SEQUENCE LISTING

<110> Soff, Gerald  
 Gately, Stephen T.  
 Twardowski, Przemyslaw

<120> METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN

<130> 4228-1-1-1

<140> Not Yet Assigned  
 <141> 2000-02-08

<150> 08/710,305  
 <151> 1996-09-17

<150> 08/991,761  
 <151> 1997-12-15

<150> PCT/US97/16539  
 <151> 1997-09-17

<160> 17

<170> PatentIn Ver. 2.1

<210> 1  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 1  
 Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly  
 1 5 10

<210> 2  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Lys Leu Tyr Asp Tyr Cys Asp Val  
 1 5

<210> 3  
 <211> 7

<212> PRT

<213> Homo sapiens

<400> 3

Leu Tyr Asp Tyr Cys Asp Val

1

5

<210> 4

<211> 7

<212> PRT

<213> Homo sapiens

<400> 4

Cys Tyr Thr Thr Asn Pro Arg

1

5

<210> 5

<211> 8

<212> PRT

<213> Homo sapiens

<400> 5

Cys Tyr Thr Thr Asn Pro Arg Lys

1

5

<210> 6

<211> 791

<212> PRT

<213> Homo sapiens

<400> 6

Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser Leu Phe Ser

1

5

10

15

Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu Cys Ala Ala

20

25

30

Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe Gln Tyr His

35

40

45

Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg Lys Ser Ser

50

55

60

Ile Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys Lys Val Tyr

65

70

75

80

Leu	Ser	Glu	Cys	Lys	Thr	Gly	Asn	Gly	Lys	Asn	Tyr	Arg	Gly	Thr	Met	85	90	95	
Ser	Lys	Thr	Lys	Asn	Gly	Ile	Thr	Cys	Gln	Lys	Trp	Ser	Ser	Thr	Ser	100	105	110	
Pro	His	Arg	Pro	Arg	Phe	Ser	Pro	Ala	Thr	His	Pro	Ser	Glu	Gly	Leu	115	120	125	
Glu	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Asn	Asp	Pro	Gln	Gly	Pro	Trp	130	135	140	
Cys	Tyr	Thr	Thr	Asp	Pro	Glu	Lys	Arg	Tyr	Asp	Tyr	Cys	Asp	Ile	Leu	145	150	155	160
Glu	Cys	Glu	Glu	Glu	Cys	Met	His	Cys	Ser	Gly	Glu	Asn	Tyr	Asp	Gly	165	170	175	
Lys	Ile	Ser	Lys	Thr	Met	Ser	Gly	Leu	Glu	Cys	Gln	Ala	Trp	Asp	Ser	180	185	190	
Gln	Ser	Pro	His	Ala	His	Gly	Tyr	Ile	Pro	Ser	Lys	Phe	Pro	Asn	Lys	195	200	205	
Asn	Leu	Lys	Lys	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Arg	Glu	Leu	Arg	Pro	210	215	220	
Trp	Cys	Phe	Thr	Thr	Asp	Pro	Asn	Lys	Arg	Trp	Glu	Leu	Cys	Asp	Ile	225	230	235	240
Pro	Arg	Cys	Thr	Thr	Pro	Pro	Pro	Ser	Ser	Gly	Pro	Thr	Tyr	Gln	Cys	245	250	255	
Leu	Lys	Gly	Thr	Gly	Glu	Asn	Tyr	Arg	Gly	Asn	Val	Ala	Val	Thr	Val	260	265	270	
Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	Thr	Pro	His	Thr	His	275	280	285	
Asn	Arg	Thr	Pro	Glu	Asn	Phe	Pro	Cys	Lys	Asn	Leu	Asp	Glu	Asn	Tyr	290	295	300	
Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	Cys	His	Thr	Thr	Asn	305	310	315	320
Ser	Gln	Val	Arg	Trp	Glu	Tyr	Cys	Lys	Ile	Pro	Ser	Cys	Asp	Ser	Ser	325	330	335	

Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu Leu Thr  
 340 345 350

Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly  
 355 360 365

Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser  
 370 375 380

Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala  
 385 390 395 400

Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro  
 405 410 415

Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu  
 420 425 430

Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro Pro Pro Val  
 435 440 445

Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp Cys Met Phe  
 450 455 460

Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr Val Thr Gly  
 465 470 475 480

Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg His Ser Ile  
 485 490 495

Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys Asn Tyr Cys  
 500 505 510

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr Thr Thr Asn  
 515 520 525

Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys Ala Ala Pro  
 530 535 540

Ser Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys Cys Pro Gly  
 545 550 555 560

Arg Val Val Gly Gly Cys Val Ala His Pro His Ser Trp Pro Trp Gln  
 565 570 575

Val Ser Leu Arg Thr Arg Phe Gly Met His Phe Cys Gly Gly Thr Leu  
 580 585 590

Ile Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu Glu Lys Ser  
595 600 605

Pro Arg Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His Gln Glu Val  
610 615 620

Asn Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Arg Leu Phe Leu  
625 630 635 640

Glu Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser Ser Pro Ala  
645 650 655

Val Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser Pro Asn Tyr  
660 665 670

Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp Gly Glu Thr  
675 680 685

Gln Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln Leu Pro Val  
690 695 700

Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn Gly Arg Val  
705 710 715 720

Gln Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly Thr Asp Ser  
725 730 735

Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu Lys Asp Lys  
740 745 750

Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys Ala Arg Pro  
755 760 765

Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val Thr Trp Ile  
770 775 780

Glu Gly Val Met Arg Asn Asn  
785 790

<210> 7

<211> 812

<212> PRT

<213> Bos taurus

<400> 7

Met Leu Pro Ala Ser Pro Lys Met Glu His Lys Ala Val Val Phe Leu



1	5	10	15
Leu Leu Leu Phe Leu Lys Ser Gly Leu Gly Asp Leu Leu Asp Asp Tyr	20	25	30
Val Asn Thr Gln Gly Ala Ser Leu Leu Ser Leu Ser Arg Lys Asn Leu	35	40	45
Ala Gly Arg Ser Val Glu Asp Cys Ala Ala Lys Cys Glu Glu Glu Thr	50	55	60
Asp Phe Val Cys Arg Ala Phe Gln Tyr His Ser Lys Glu Gln Gln Cys	65	70	75
Val Val Met Ala Glu Asn Ser Lys Asn Thr Pro Val Phe Arg Met Arg	85	90	95
Asp Val Ile Leu Tyr Glu Lys Arg Ile Tyr Leu Leu Glu Cys Lys Thr	100	105	110
Gly Asn Gly Gln Thr Tyr Arg Gly Thr Thr Ala Glu Thr Lys Ser Gly	115	120	125
Val Thr Cys Gln Lys Trp Ser Ala Thr Ser Pro His Val Pro Lys Phe	130	135	140
Ser Pro Glu Lys Phe Pro Leu Ala Gly Leu Glu Glu Asn Tyr Cys Arg	145	150	155
Asn Pro Asp Asn Asp Glu Asn Gly Pro Trp Cys Tyr Thr Thr Asp Pro	165	170	175
Asp Lys Arg Tyr Asp Tyr Cys Asp Ile Pro Glu Cys Glu Asp Lys Cys	180	185	190
Met His Cys Ser Gly Glu Asn Tyr Glu Gly Lys Ile Ala Lys Thr Met	195	200	205
Ser Gly Arg Asp Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala His	210	215	220
Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Met Asn Tyr	225	230	235
Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro Trp Cys Phe Thr Thr Asp	245	250	255
Pro Gln Lys Arg Trp Glu Phe Cys Asp Ile Pro Arg Cys Thr Thr Pro			

260	265	270
Pro Pro Ser Ser Gly Pro Lys Tyr Gln Cys Leu Lys Gly Thr Gly Lys		
275	280	285
Asn Tyr Gly Gly Thr Val Ala Val Thr Glu Ser Gly His Thr Cys Gln		
290	295	300
Arg Trp Ser Glu Gln Thr Pro His Lys His Asn Arg Thr Pro Glu Asn		
305	310	315
Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asn Gly		
325	330	335
Glu Lys Ala Pro Trp Cys Tyr Thr Thr Asn Ser Glu Val Arg Trp Glu		
340	345	350
Tyr Cys Thr Ile Pro Ser Cys Glu Ser Ser Pro Leu Ser Thr Glu Arg		
355	360	365
Met Asp Val Pro Val Pro Pro Glu Gln Thr Pro Val Pro Gln Asp Cys		
370	375	380
Tyr His Gly Asn Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr Ile		
385	390	395
Thr Gly Arg Lys Cys Gln Ser Trp Ser Ser Met Thr Pro His Arg His		
405	410	415
Leu Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly Leu Thr Met Asn Tyr		
420	425	430
Cys Arg Asn Pro Asp Ala Asp Lys Ser Pro Trp Cys Tyr Thr Thr Asp		
435	440	445
Pro Arg Val Arg Trp Glu Phe Cys Asn Leu Lys Lys Cys Ser Glu Thr		
450	455	460
Pro Glu Gln Val Pro Ala Ala Pro Gln Ala Pro Gly Val Glu Asn Pro		
465	470	475
Pro Glu Ala Asp Cys Met Ile Gly Thr Gly Lys Ser Tyr Arg Gly Lys		
485	490	495
Lys Ala Thr Thr Val Ala Gly Val Pro Cys Gln Glu Trp Ala Ala Gln		
500	505	510
Glu Pro His Gln His Ser Ile Phe Thr Pro Glu Thr Asn Pro Gln Ser		

515		520		525
Gly Leu Glu Arg Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Asn Gly				
530		535		540
Pro Trp Cys Tyr Thr Met Asn Pro Arg Lys Pro Phe Asp Tyr Cys Asp				
545		550		555
				560
Val Pro Gln Cys Glu Ser Ser Phe Asp Cys Gly Lys Pro Lys Val Glu				
	565		570	575
Pro Lys Lys Cys Ser Gly Arg Ile Val Gly Gly Cys Val Ser Lys Pro				
	580		585	590
His Ser Trp Pro Trp Gln Val Ser Leu Arg Arg Ser Ser Arg His Phe				
	595		600	605
Cys Gly Gly Thr Leu Ile Ser Pro Lys Trp Val Leu Thr Ala Ala His				
	610		615	620
Cys Leu Asp Asn Ile Leu Ala Leu Ser Phe Tyr Lys Val Ile Leu Gly				
	625		630	635
				640
Ala His Asn Glu Lys Val Arg Glu Gln Ser Val Gln Glu Ile Pro Val				
	645		650	655
Ser Arg Leu Phe Arg Glu Pro Ser Gln Ala Asp Ile Ala Leu Leu Lys				
	660		665	670
Leu Ser Arg Pro Ala Ile Ile Thr Lys Glu Val Ile Pro Ala Cys Leu				
	675		680	685
Pro Pro Pro Asn Tyr Met Val Ala Ala Arg Thr Glu Cys Tyr Ile Thr				
	690		695	700
Gly Trp Gly Glu Thr Gln Gly Thr Phe Gly Glu Gly Leu Leu Lys Glu				
	705		710	715
				720
Ala His Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Asn Glu Tyr				
	725		730	735
Leu Asp Gly Arg Val Lys Pro Thr Glu Leu Cys Ala Gly His Leu Ile				
	740		745	750
Gly Gly Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys				
	755		760	765
Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu				

770

775

780

Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Pro  
785 790 795 800

Tyr Val Pro Trp Ile Glu Glu Thr Met Arg Arg Asn  
805 810

&lt;210&gt; 8

&lt;211&gt; 333

&lt;212&gt; PRT

&lt;213&gt; Canis familiaris

&lt;400&gt; 8

Ala Ser Asp Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Lys  
1 5 10 15

Ala Thr Thr Val Met Gly Ile Pro Cys Gln Glu Trp Ala Ala Gln Glu  
20 25 30

Pro His Arg His Ser Ile Phe Thr Pro Glu Thr Asn Pro Gln Ala Gly  
35 40 45

Leu Glu Lys Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Asn Gly Pro  
50 55 60

Trp Cys Tyr Thr Met Asn Gln Arg Lys Leu Phe Asp Tyr Cys Asp Val  
65 70 75 80

Pro Gln Cys Val Ser Thr Ser Phe Asp Cys Gly Lys Pro Gln Val Glu  
85 90 95

Pro Lys Lys Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala Asn Pro  
100 105 110

His Ser Trp Pro Trp Gln Ile Ser Leu Arg Thr Arg Tyr Gly Lys His  
115 120 125

Phe Cys Gly Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr Ala Ala  
130 135 140

His Cys Leu Glu Arg Ser Ser Arg Pro Ala Ser Tyr Lys Val Ile Leu  
145 150 155 160

Gly Ala His Lys Glu Val Asn Leu Glu Ser Asp Val Gln Glu Ile Glu  
165 170 175

Val Tyr Lys Leu Phe Leu Glu Pro Thr Arg Ala Asp Ile Ala Leu Leu  
180 185 190

Lys Leu Ser Ser Pro Ala Val Ile Thr Ser Lys Val Ile Pro Ala Cys  
195 200 205

Leu Pro Pro Pro Asn Tyr Val Val Ala Asp Arg Thr Leu Cys Tyr Ile  
210 215 220

Thr Gly Trp Gly Glu Thr Gln Gly Thr Tyr Gly Ala Gly Leu Leu Lys  
225 230 235 240

Glu Ala Gln Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu  
245 250 255

Tyr Leu Asn Gly Arg Val Lys Ser Thr Glu Leu Cys Ala Gly Asn Leu  
260 265 270

Ala Gly Gly Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val  
275 280 285

Cys Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly  
290 295 300

Leu Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser  
305 310 315 320

Arg Phe Val Thr Trp Ile Glu Gly Ile Met Arg Asn Asn  
325 330

<210> 9

<211> 809

<212> PRT

<213> *Erinaceus europaeus*

<400> 9

Met Gln Arg Lys Glu Leu Val Leu Leu Phe Leu Leu Phe Leu Gln Pro  
1 5 10 15

Gly His Gly Ile Pro Leu Asp Asp Tyr Val Thr Thr Gln Gly Ala Ser  
20 25 30

Leu Cys Ser Ser Thr Lys Lys Gln Leu Ser Val Gly Ser Thr Glu Glu  
35 40 45

Cys Ala Val Lys Cys Glu Lys Glu Thr Ser Phe Ile Cys Arg Ser Phe  
50 55 60

Gln	Tyr	His	Ser	Lys	Glu	Gln	Gln	Cys	Val	Ile	Met	Ala	Glu	Asn	Ser		
65					70					75					80		
Lys	Ser	Thr	Pro	Val	Leu	Arg	Met	Arg	Asp	Val	Ile	Leu	Phe	Glu	Lys		
				85					90					95			
Lys	Met	Tyr	Leu	Ser	Glu	Cys	Lys	Val	Gly	Asn	Gly	Lys	Tyr	Tyr	Arg		
			100					105					110				
Gly	Thr	Val	Ser	Lys	Thr	Lys	Thr	Gly	Leu	Thr	Cys	Gln	Lys	Trp	Ser		
	115						120					125					
Ala	Glu	Thr	Pro	His	Lys	Pro	Arg	Phe	Ser	Pro	Asp	Glu	Asn	Pro	Ser		
	130					135					140						
Glu	Gly	Leu	Asp	Gln	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Asn	Asp	Pro	Lys		
145					150					155					160		
Gly	Pro	Trp	Cys	Tyr	Thr	Met	Asp	Pro	Glu	Val	Arg	Tyr	Glu	Tyr	Cys		
			165						170					175			
Glu	Ile	Ile	Gln	Cys	Glu	Asp	Glu	Cys	Met	His	Cys	Ser	Gly	Gln	Asn		
			180					185					190				
Tyr	Val	Gly	Lys	Ile	Ser	Arg	Thr	Met	Ser	Gly	Leu	Glu	Cys	Gln	Pro		
	195						200					205					
Trp	Asp	Ser	Gln	Ile	Pro	His	Pro	His	Gly	Phe	Ile	Pro	Ser	Lys	Phe		
	210					215					220						
Pro	Ser	Lys	Asn	Leu	Lys	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Glu		
225					230					235					240		
Pro	Arg	Pro	Trp	Cys	Phe	Thr	Met	Asp	Arg	Asn	Lys	Arg	Trp	Glu	Tyr		
			245					250						255			
Cys	Asp	Ile	Pro	Arg	Cys	Thr	Thr	Pro	Pro	Pro	Pro	Ser	Gly	Pro	Thr		
			260					265					270				
Tyr	Gln	Cys	Leu	Met	Gly	Asn	Gly	Glu	His	Tyr	Gln	Gly	Asn	Val	Ala		
	275						280					285					
Val	Thr	Val	Ser	Gly	Leu	Thr	Cys	Gln	Arg	Trp	Gly	Glu	Gln	Ser	Pro		
	290					295					300						
His	Arg	His	Asp	Arg	Thr	Pro	Glu	Asn	Tyr	Pro	Cys	Lys	Asn	Leu	Asp		
305					310				315						320		

Glu Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro Ala Pro Trp Cys Phe  
 325 330 335

Thr Thr Asn Ser Ser Val Arg Trp Glu Phe Cys Lys Ile Pro Asp Cys  
 340 345 350

Val Ser Ser Ala Ser Glu Thr Glu His Ser Asp Ala Pro Val Ile Val  
 355 360 365

Pro Pro Glu Gln Thr Pro Val Val Gln Glu Cys Tyr Gln Gly Asn Gly  
 370 375 380

Gln Thr Tyr Arg Gly Thr Ser Ser Thr Thr Ile Thr Gly Lys Lys Cys  
 385 390 395 400

Gln Pro Trp Thr Ser Met Arg Pro His Arg His Ser Lys Thr Pro Glu  
 405 410 415

Asn Tyr Pro Asp Ala Asp Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp  
 420 425 430

Gly Asp Lys Gly Pro Trp Cys Tyr Thr Thr Asp Pro Ser Val Arg Trp  
 435 440 445

Glu Phe Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Met Ser Ala Thr  
 450 455 460

Asn Ser Ser Pro Val Gln Val Ser Ser Ala Ser Glu Ser Ser Glu Gln  
 465 470 475 480

Asp Cys Ile Ile Asp Asn Gly Lys Gly Tyr Arg Gly Thr Lys Ala Thr  
 485 490 495

Thr Gly Ala Gly Thr Pro Cys Gln Ala Trp Ala Ala Gln Glu Pro His  
 500 505 510

Arg His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Asp Leu Gln  
 515 520 525

Glu Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Asn Gly Pro Trp Cys  
 530 535 540

Tyr Thr Thr Asn Pro Arg Lys Leu Phe Asp Tyr Cys Asp Ile Pro His  
 545 550 555 560

Cys Val Ser Pro Ser Ser Ala Asp Cys Gly Lys Pro Lys Val Glu Pro  
 565 570 575

Lys Lys Cys Pro Gly Arg Val Gly Gly Cys Val Ala His Pro His Ser  
 580 585 590  
 Trp Pro Trp Gln Val Ser Leu Arg Arg Phe Gly Gln His Phe Cys Gly  
 595 600 605  
 Gly Thr Leu Ile Ser Pro Glu Trp Val Val Thr Ala Ala His Cys Leu  
 610 615 620  
 Glu Lys Phe Ser Asn Pro Ala Ile Tyr Lys Val Val Leu Gly Ala His  
 625 630 635 640  
 Gln Glu Thr Arg Leu Glu Arg Asp Val Gln Ile Lys Gly Val Thr Lys  
 645 650 655  
 Met Phe Leu Glu Pro Tyr Arg Ala Asp Ile Ala Leu Leu Lys Leu Ser  
 660 665 670  
 Ser Pro Ala Ile Ile Thr Asp Lys Asp His Pro Ala Cys Leu Pro Asn  
 675 680 685  
 Ser Asn Tyr Met Val Ala Asp Arg Ser Leu Cys Tyr Ile Thr Gly Trp  
 690 695 700  
 Gly Glu Thr Lys Gly Thr Tyr Gly Ala Gly Leu Leu Lys Glu Ala Gln  
 705 710 715 720  
 Leu Pro Val Ile Glu Lys Val Cys Asn Arg Gln Ser Phe Leu Asn Gly  
 725 730 735  
 Arg Val Arg Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly Val  
 740 745 750  
 Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu Lys  
 755 760 765  
 Asp Arg Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys Ala  
 770 775 780  
 Arg Leu Thr Arg Pro Gly Val Tyr Val Arg Val Ser Arg Tyr Val Ser  
 785 790 795 800  
 Trp Leu Gln Asp Val Met Arg Asn Asn  
 805

<210> 10



<211> 338

<212> PRT

<213> Equus caballus

<400> 10

Val Gln Glu Pro Ser Glu Pro Asp Cys Met Leu Gly Ile Gly Lys Gly  
1 5 10 15

Tyr Gln Gly Lys Lys Ala Thr Thr Val Thr Gly Thr Arg Cys Gln Ala  
20 25 30

Trp Ala Ala Gln Glu Pro His Arg His Ser Ile Phe Thr Pro Glu Ala  
35 40 45

Asn Pro Trp Ala Asn Leu Glu Lys Asn Tyr Cys Arg Asn Pro Asp Gly  
50 55 60

Asp Val Asn Gly Pro Trp Cys Tyr Thr Met Asn Pro Gln Lys Leu Phe  
65 70 75 80

Asp Tyr Cys Asp Val Pro Gln Cys Glu Ser Ser Pro Phe Asp Cys Gly  
85 90 95

Lys Pro Lys Val Glu Pro Lys Lys Cys Ser Gly Arg Ile Val Gly Gly  
100 105 110

Cys Val Ala Ile Ala His Ser Trp Pro Trp Gln Ile Ser Leu Arg Thr  
115 120 125

Arg Phe Gly Arg His Phe Cys Gly Gly Thr Leu Ile Ser Pro Glu Trp  
130 135 140

Val Leu Thr Ala Ala His Cys Leu Glu Arg Ser Ser Arg Pro Ser Thr  
145 150 155 160

Tyr Lys Val Val Leu Gly Thr His His Glu Leu Arg Leu Ala Ala Gly  
165 170 175

Ala Gln Gln Ile Asp Val Ser Lys Leu Phe Leu Glu Pro Ser Arg Ala  
180 185 190

Asp Ile Ala Leu Leu Lys Leu Ser Ser Pro Ala Ile Ile Thr Gln Asn  
195 200 205

Val Ile Pro Ala Cys Leu Pro Pro Ala Asp Tyr Val Val Ala Asn Trp  
210 215 220

Ala Glu Cys Phe Val Thr Gly Trp Gly Glu Thr Gln Asp Ser Ser Asn

225                      230                      235                      240  
 Ala Gly Val Leu Lys Glu Ala Gln Leu Pro Val Ile Glu Asn Lys Val  
                                  245                      250                      255  
 Cys Asn Arg Tyr Glu Tyr Leu Asn Gly Arg Val Lys Ser Thr Glu Leu  
                                  260                      265                      270  
 Cys Ala Gly His Leu Val Gly Gly Val Asp Ser Cys Gln Gly Asp Ser  
                                  275                      280                      285  
 Gly Gly Pro Leu Val Cys Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly  
                                  290                      295                      300  
 Val Thr Ser Trp Gly Leu Gly Cys Ala Arg Pro Asn Lys Pro Gly Val  
 305                                   310                      315                      320  
 Tyr Val Arg Val Ser Ser Phe Ile Asn Trp Ile Glu Arg Ile Met Gln  
                                  325                      330                      335

Ser Asn

<210> 11

<211> 810

<212> PRT

<213> Macaca mulatta

<400> 11

Met Glu His Lys Glu Val Val Leu Leu Leu Leu Leu Phe Leu Lys Ser  
   1                                      5                                      10                                      15  
 Gly Gln Gly Glu Pro Leu Asp Asp Tyr Val Asn Thr Lys Gly Ala Ser  
                                  20                                      25                                      30  
 Leu Phe Ser Ile Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu  
                                  35                                      40                                      45  
 Cys Ala Ala Lys Cys Glu Glu Glu Glu Glu Phe Thr Cys Arg Ser Phe  
                                  50                                      55                                      60  
 Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg  
   65                                      70                                      75                                      80  
 Lys Ser Ser Ile Val Phe Arg Met Arg Asp Val Val Leu Phe Glu Lys  
                                  85                                      90                                      95

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg  
 100 105 110

Gly Thr Met Ser Lys Thr Arg Thr Gly Ile Thr Cys Gln Lys Trp Ser  
 115 120 125

Ser Thr Ser Pro His Arg Pro Thr Phe Ser Pro Ala Thr His Pro Ser  
 130 135 140

Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Gly Gln  
 145 150 155 160

Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Glu Arg Phe Asp Tyr Cys  
 165 170 175

Asp Ile Pro Glu Cys Glu Asp Glu Cys Met His Cys Ser Gly Glu Asn  
 180 185 190

Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala  
 195 200 205

Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe  
 210 215 220

Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Gly Glu  
 225 230 235 240

Pro Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu  
 245 250 255

Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr  
 260 265 270

Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asp Val Ala  
 275 280 285

Val Thr Val Ser Gly His Thr Cys His Gly Trp Ser Ala Gln Thr Pro  
 290 295 300

His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp  
 305 310 315 320

Glu Asn Tyr Cys Arg Asn Pro Asp Gly Glu Lys Ala Pro Trp Cys Tyr  
 325 330 335

Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys  
 340 345 350

Glu Ser Ser Pro Val Ser Thr Glu Pro Leu Asp Pro Thr Ala Pro Pro	355	360	365
Glu Leu Thr Pro Val Val Gln Glu Cys Tyr His Gly Asp Gly Gln Ser	370	375	380
Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser	385	390	395
Trp Ser Ser Met Thr Pro His Trp His Glu Lys Thr Pro Glu Asn Phe	405	410	415
Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp	420	425	430
Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr	435	440	445
Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Gly Ser Val Ala Ala Pro	450	455	460
Pro Pro Val Ala Gln Leu Pro Asp Ala Glu Thr Pro Ser Glu Glu Asp	465	470	475
Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Lys Ala Thr Thr	485	490	495
Val Thr Gly Thr Pro Cys Gln Glu Trp Ala Ala Gln Glu Pro His Ser	500	505	510
His Arg Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys	515	520	525
Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr	530	535	540
Thr Thr Asn Pro Arg Lys Leu Phe Asp Tyr Cys Asp Val Pro Gln Cys	545	550	555
Ala Ala Ser Ser Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys	565	570	575
Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala Tyr Pro His Ser Trp	580	585	590
Pro Trp Gln Ile Ser Leu Arg Thr Arg Leu Gly Met His Phe Cys Gly	595	600	605

Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu  
 610 615 620  
 Glu Lys Ser Ser Arg Pro Ser Phe Tyr Lys Val Ile Leu Gly Ala His  
 625 630 635 640  
 Arg Glu Val His Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Lys  
 645 650 655  
 Met Phe Ser Glu Pro Ala Arg Ala Asp Ile Ala Leu Leu Lys Leu Ser  
 660 665 670  
 Ser Pro Ala Ile Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser  
 675 680 685  
 Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp  
 690 695 700  
 Gly Glu Thr Gln Gly Thr Tyr Gly Ala Gly Leu Leu Lys Glu Ala Arg  
 705 710 715 720  
 Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn  
 725 730 735  
 Gly Thr Val Lys Thr Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly  
 740 745 750  
 Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu  
 755 760 765  
 Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys  
 770 775 780  
 Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val  
 785 790 795 800  
 Thr Trp Ile Glu Gly Val Met Arg Asn Asn  
 805 810

<210> 12

<211> 812

<212> PRT

<213> Mus musculus

<400> 12

Met Asp His Lys Glu Val Ile Leu Leu Phe Leu Leu Leu Leu Lys Pro  
 1 5 10 15

Gly Gln Gly Asp Ser Leu Asp Gly Tyr Ile Ser Thr Gln Gly Ala Ser  
 20 25 30  
 Leu Phe Ser Leu Thr Lys Lys Gln Leu Ala Ala Gly Gly Val Ser Asp  
 35 40 45  
 Cys Leu Ala Lys Cys Glu Gly Glu Thr Asp Phe Val Cys Arg Ser Phe  
 50 55 60  
 Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Ser  
 65 70 75 80  
 Lys Thr Ser Ser Ile Ile Arg Met Arg Asp Val Ile Leu Phe Glu Lys  
 85 90 95  
 Arg Val Tyr Leu Ser Glu Cys Lys Thr Gly Ile Gly Asn Gly Tyr Arg  
 100 105 110  
 Gly Thr Met Ser Arg Thr Lys Ser Gly Val Ala Cys Gln Lys Trp Gly  
 115 120 125  
 Ala Thr Phe Pro His Val Pro Asn Tyr Ser Pro Ser Thr His Pro Asn  
 130 135 140  
 Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Glu Gln  
 145 150 155 160  
 Gly Pro Trp Cys Tyr Thr Thr Asp Pro Asp Lys Arg Tyr Asp Tyr Cys  
 165 170 175  
 Asn Ile Pro Glu Cys Glu Glu Glu Cys Met Tyr Cys Ser Gly Glu Lys  
 180 185 190  
 Tyr Glu Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Asp Cys Gln Ala  
 195 200 205  
 Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ala Lys Phe  
 210 215 220  
 Pro Ser Lys Asn Leu Lys Met Asn Tyr Cys His Asn Pro Asp Gly Glu  
 225 230 235 240  
 Pro Arg Pro Trp Cys Phe Thr Thr Asp Pro Thr Lys Arg Trp Glu Tyr  
 245 250 255  
 Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Pro Pro Ser Pro Thr  
 260 265 270

Tyr Gln Cys Leu Lys Gly Arg Gly Glu Asn Tyr Arg Gly Thr Val Ser  
 275 280 285

Val Thr Val Ser Gly Lys Thr Cys Gln Arg Trp Ser Glu Gln Thr Pro  
 290 295 300

His Arg His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu  
 305 310 315 320

Glu Asn Tyr Cys Arg Asn Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr  
 325 330 335

Thr Thr Asp Ser Gln Leu Arg Trp Glu Tyr Cys Glu Ile Pro Ser Cys  
 340 345 350

Glu Ser Ser Ala Ser Pro Asp Gln Ser Asp Ser Ser Val Pro Pro Glu  
 355 360 365

Glu Gln Thr Pro Val Val Gln Glu Cys Tyr Gln Ser Asp Gly Gln Ser  
 370 375 380

Tyr Arg Gly Thr Ser Ser Thr Thr Ile Thr Gly Lys Lys Cys Gln Ser  
 385 390 395 400

Trp Ala Ala Met Phe Pro His Arg His Ser Lys Thr Pro Glu Asn Phe  
 405 410 415

Pro Asp Ala Gly Leu Glu Met Asn Tyr Cys Arg Asn Pro Asp Gly Asp  
 420 425 430

Lys Gly Pro Trp Cys Tyr Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr  
 435 440 445

Cys Asn Leu Lys Arg Cys Ser Glu Thr Gly Gly Ser Val Val Glu Leu  
 450 455 460

Pro Thr Val Ser Gln Glu Pro Ser Gly Pro Ser Asp Ser Glu Thr Asp  
 465 470 475 480

Cys Met Tyr Gly Asn Gly Lys Asp Tyr Arg Gly Lys Thr Ala Val Thr  
 485 490 495

Ala Ala Gly Thr Pro Cys Gln Gly Trp Ala Ala Gln Glu Pro His Arg  
 500 505 510

His Ser Ile Phe Thr Pro Gln Thr Asn Pro Arg Ala Asp Leu Glu Lys  
 515 520 525

Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Asn Gly Pro Trp Cys Tyr  
 530 535 540

Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Ile Pro Leu Cys  
 545 550 555 560

Ala Ser Ala Ser Ser Phe Glu Cys Gly Lys Pro Gln Val Glu Pro Lys  
 565 570 575

Lys Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala Asn Pro His Ser  
 580 585 590

Trp Pro Trp Gln Ile Ser Leu Arg Thr Arg Phe Thr Gly Gln His Phe  
 595 600 605

Cys Gly Gly Thr Leu Ile Ala Pro Glu Trp Val Leu Thr Ala Ala His  
 610 615 620

Cys Leu Glu Lys Ser Ser Arg Pro Glu Phe Tyr Lys Val Ile Leu Gly  
 625 630 635 640

Ala His Glu Glu Tyr Ile Arg Gly Leu Asp Val Gln Glu Ile Ser Val  
 645 650 655

Ala Lys Leu Ile Leu Glu Pro Asn Asn Arg Asp Ile Ala Leu Leu Lys  
 660 665 670

Leu Ser Arg Pro Ala Thr Ile Thr Asp Lys Val Ile Pro Ala Cys Leu  
 675 680 685

Pro Ser Pro Asn Tyr Met Val Ala Asp Arg Thr Ile Cys Tyr Ile Thr  
 690 695 700

Gly Trp Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Arg Leu Lys Glu  
 705 710 715 720

Ala Gln Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Val Glu Tyr  
 725 730 735

Leu Asn Asn Arg Val Lys Ser Thr Glu Leu Cys Ala Gly Gln Leu Ala  
 740 745 750

Gly Gly Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys  
 755 760 765

Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu  
 770 775 780



Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg  
785 790 795 800

Phe Val Asp Trp Ile Glu Arg Glu Met Arg Asn Asn  
805 810

<210> 13

<211> 790

<212> PRT

<213> Sus scrofa

<400> 13

Asp Ser Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Phe Leu Phe Ser  
1 5 10 15

Leu Ser Arg Lys Gln Val Ala Ala Arg Ser Val Glu Glu Cys Ala Ala  
20 25 30

Lys Cys Glu Ala Glu Thr Asn Phe Ile Cys Arg Ala Phe Gln Tyr His  
35 40 45

Ser Lys Asp Gln Gln Cys Val Val Met Ala Glu Asn Ser Lys Thr Ser  
50 55 60

Pro Ile Ala Arg Met Arg Asp Val Val Leu Phe Glu Lys Arg Ile Tyr  
65 70 75 80

Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Thr  
85 90 95

Ser Lys Thr Lys Ser Gly Val Ile Cys Gln Lys Trp Ser Val Ser Ser  
100 105 110

Pro His Ile Pro Lys Tyr Ser Pro Glu Lys Phe Pro Leu Ala Gly Leu  
115 120 125

Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Glu Lys Gly Pro Trp  
130 135 140

Cys Tyr Thr Thr Asp Pro Glu Thr Arg Phe Asp Tyr Cys Asp Ile Pro  
145 150 155 160

Glu Cys Glu Asp Glu Cys Met His Cys Ser Gly Glu His Tyr Glu Gly  
165 170 175

Lys Ile Ser Lys Thr Met Ser Gly Ile Glu Cys Gln Ser Trp Gly Ser

180	185	190
Gln Ser Pro His Ala His Gly Tyr Leu Pro Ser Lys Phe Pro Asn Lys		
195	200	205
Asn Leu Lys Met Asn Tyr Cys Arg Asn Pro Asp Gly Glu Pro Arg Pro		
210	215	220
Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Phe Cys Asp Ile		
225	230	235
Pro Arg Cys Thr Thr Pro Pro Pro Thr Ser Gly Pro Thr Tyr Gln Cys		
	245	250
		255
Leu Lys Gly Arg Gly Glu Asn Tyr Arg Gly Thr Val Ser Val Thr Ala		
	260	265
		270
Ser Gly His Thr Cys Gln Arg Trp Ser Ala Gln Ser Pro His Lys His		
	275	280
		285
Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Glu Glu Asn Tyr		
	290	295
		300
Cys Arg Asn Pro Asp Gly Glu Thr Ala Pro Trp Cys Tyr Thr Thr Asp		
	305	310
		315
Ser Glu Val Arg Trp Asp Tyr Cys Lys Ile Pro Ser Cys Gly Ser Ser		
	325	330
		335
Thr Thr Ser Thr Glu His Leu Asp Ala Pro Val Pro Pro Glu Gln Thr		
	340	345
		350
Pro Val Ala Gln Asp Cys Tyr Arg Gly Asn Gly Glu Ser Tyr Arg Gly		
	355	360
		365
Thr Ser Ser Thr Thr Ile Thr Gly Arg Lys Cys Gln Ser Trp Val Ser		
	370	375
		380
Met Thr Pro His Arg His Glu Lys Thr Pro Gly Asn Phe Pro Asn Ala		
	385	390
		395
Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Ser Pro		
	405	410
		415
Trp Cys Tyr Thr Thr Asp Pro Arg Val Arg Trp Glu Tyr Cys Asn Leu		
	420	425
		430
Lys Lys Cys Ser Glu Thr Glu Gln Gln Val Thr Asn Phe Pro Ala Ile		

435	440	445
Ala Gln Val Pro Ser Val Glu Asp Leu Ser Glu Asp Cys Met Phe Gly		
450	455	460
Asn Gly Lys Arg Tyr Arg Gly Lys Arg Ala Thr Thr Val Ala Gly Val		
465	470	475 480
Pro Cys Gln Glu Trp Ala Ala Gln Glu Pro His Arg His Ser Ile Phe		
485	490	495
Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys Asn Tyr Cys Arg		
500	505	510
Asn Pro Asp Gly Asp Asp Asn Gly Pro Trp Cys Tyr Thr Thr Asn Pro		
515	520	525
Gln Lys Leu Phe Asp Tyr Cys Asp Val Pro Gln Cys Val Thr Ser Ser		
530	535	540
Phe Asp Cys Gly Lys Pro Lys Val Glu Pro Lys Lys Cys Pro Ala Arg		
545	550	555 560
Val Val Gly Gly Cys Val Ser Ile Pro His Ser Trp Pro Trp Gln Ile		
565	570	575
Ser Leu Arg Tyr Arg Tyr Arg Gly His Phe Cys Gly Gly Thr Leu Ile		
580	585	590
Ser Pro Glu Trp Val Leu Thr Ala Lys His Cys Leu Glu Lys Ser Ser		
595	600	605
Ser Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His Glu Glu Tyr His		
610	615	620
Leu Gly Glu Gly Val Gln Glu Ile Asp Val Ser Lys Leu Phe Lys Glu		
625	630	635 640
Pro Ser Glu Ala Asp Ile Ala Leu Leu Lys Leu Ser Ser Pro Ala Val		
645	650	655
Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Thr Pro Asn Tyr Val		
660	665	670
Val Ala Asp Arg Thr Ala Cys Tyr Ile Thr Gly Trp Gly Glu Thr Lys		
675	680	685
Gly Thr Tyr Gly Ala Gly Leu Leu Lys Glu Ala Arg Leu Pro Val Ile		

690	695	700
Glu Asn Lys Val Cys Asn Arg Tyr Glu Tyr Leu Gly Gly Lys Val Ser		
705	710	715 720
Pro Asn Glu Leu Cys Ala Gly His Leu Ala Gly Gly Ile Asp Ser Cys		
725	730	735
Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu Lys Asp Lys Tyr		
740	745	750
Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys Ala Leu Pro Asn		
755	760	765
Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val Thr Trp Ile Glu		
770	775	780
Glu Ile Met Arg Arg Asn		
785	790	

<210> 14  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:synthetic,  
 hypothetical

<400> 14  
 hawaaugucu

10

<210> 15  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:synthetic,  
 substrate

<400> 15  
 Ala Ala Pro Val

1

<210> 16  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:synthetic,  
 substrate

<400> 16  
 Ala Ala Pro Ala  
 1

<210> 17  
 <211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr Thr Thr Asn  
 1 5 10 15

Pro Arg